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ABSTRACT OF THE DISSERTATION
Lymphatic Filariasis: Host and Parasite Factors and the Pathogenesis of Systemic Adverse
Events Following Treatment
by
Britt Juul Andersen
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Microbiology and Microbial Pathogenesis
Washington University in St. Louis, 2020
Professor Gary J. Weil, Chair

Lymphatic filariasis (LF) is a neglected tropical disease caused by the nematode parasites
Wuchereria bancrofti, Brugia malayi and B. timori. The primary tool used by the Global
Program to Eliminate LF is mass drug administration (MDA), and some 500 million people take
the medications each year. Mild to moderate adverse events (AEs) are common after LF
treatment, and these pose a major challenge for the LF elimination program. To better understand
the pathogenesis of AEs, we studied patients from LF treatment trials in Côte d’Ivoire and Papua
New Guinea, where plasma and leucocytes were collected pre and post-treatment and subjects
were monitored for AEs. We found that plasma levels of filarial antigen and DNA increased
post-treatment in individuals with AEs. We discovered that a whole range of filarial antigens
with the AD12 epitope circulate in the bloodstream 24 hours after treatment, in contrasts to the
widely accepted notion that the high molecular weight Circulating Filarial Antigen (CFA) is the
only antigen present the blood of W. bancrofti-infected individuals. We then investigated the
xii

cytokine response during AEs by measuring 27 cytokines pre and post-treatment. We identified
11-16 cytokines that increased post-treatment in individuals with AEs. This complex cytokine
response could be consistent with a LPS-like response (caused by exposure to Wolbachia
lipoprotein) with increases in TNF-α, IL-1β, IL-6, IL-1RA and IL-10.
To further delineate the host response during AEs, a transcriptomic analysis was
completed. Global RNA sequencing was performed for 9 individuals with systemic AEs and for
9 matched controls without AEs. Differential gene expression analysis identified a significant
transcriptional signature associated with post-treatment AEs; 744 genes were significantly upregulated in the AE group (post versus pre-treatment, paired). These genes were enriched for
many biological pathways, including pro-inflammatory pathways such as TLR and NF-kappa B
signaling. A machine-learning tool was used to prioritize the genes up-regulated post-treatment
in individuals with AEs, in order to identify the genes that had the best correlation between
expression levels and AE classification, and in order to identify a subset of genes to validate with
RT-qPCR. Increased expression of seven out of the top eight genes identified were validated
with RT-qPCR. TLR2 was identified by the machine-learning tool to be highly correlated to the
development of AEs, and this gene was confirmed to increase post-treatment in individuals with
AEs by RT-qPCR. These results suggest that Wolbachia lipoprotein is involved in AE
development because it is known to signal though TLR2-TLR6 and activate downstream NFkappa B. Additional support for this hypothesis was the discovery that LPS Binding Protein
(LBP) increased post-treatment in individuals with AEs, because LBP can shuttle lipoproteins to
TLR2. Improved understanding of the pathogenesis of AEs may lead to improved management
or prevention that could increase MDA compliance and hasten LF elimination.
xiii

Chapter 1:
Introduction to lymphatic filariasis

1

Preface
This chapter was written by BJA. Comments from GJW and PUF were incorporated into the
final version, presented here. Please note that this thesis and associated literature review was
completed by April 2018.
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1.1

Introduction to lymphatic filariae.

1.1.1 Overview.
Lymphatic filariasis (LF) is an important neglected tropical disease that is caused
by threadlike nematode parasites that live in the lymphatic system of the human host.
Three different lymphatic filarial species infect humans: Wuchereria bancrofti, Brugia
malayi and B. timori (1). W. bancrofti is the most widespread and it is responsible for
over 90% of human LF infections, whereas B. malayi and B. timori are limited to specific
regions in Asia (2). In the year 2000 over 120 million people were infected with one of
the three LF-causing parasites, and about 40 million of these individuals were disfigured
and disabled by the disease (3). It is estimated that 856 million individuals in 52 countries
across the world are currently threatened by LF and require preventative chemotherapy or
treatment in order to stop the spread of the infection (3).

1.1.2 Historical background.
Lymphatic filariasis is an ancient disease that was first described by Hindu and
Persian doctors around 600 B.C. (4). However, illustrations from as early as 1,500 B.C.
that possibly portray individuals suffering from elephantiasis have been found in Egypt
(Figure 1.1A) (4). Additionally, sculptures from around 500 B.C. from the Nok
civilization in West Africa may show scrotal swelling (hydroceles), another characteristic
of LF (Figure 1.1B) (5). The first definitive reports on LF are from the 16th century, when
the Dutch explorer Jan Huygen Linschoten (1563-1611) visited Goa, and reported that
the natives were “all born with one of their legs and one foot from the knee downwards
as thick as an elephants leg” (6).
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The first scientific discoveries regarding filarariasis occurred in the 19th century
when the larval form of the parasite (microfilariae or Mf) were discovered in hydrocele
fluid from a Cuban man in 1863 (7), and in the blood of an infected individual in 1872
(8). Joseph Bancroft discovered the first adult female worm in a lymph node ulcer in
1877 (4), and this filarial species was later named after him, and we now know it as W.
bancrofti. The adult male parasite was first discovered in 1888 by Sibthorpe (9). The
most prominent discovery in early filariasis research was made by the father of tropical
medicine, Sir Patrick Manson, in 1877. He found Mf in the stomach of bloodsucking
mosquitos and thereby identified the vector of the parasite, and helped elucidate the
parasite life cycle (10). This discovery is considered the birth of medical entomology, and
as one of the most significant discoveries in the field of tropical medicine, with
implications that went beyond helminthology into research areas such as malaria and
arboviruses.
Despite the advancement in the field of LF research, treatment for the disease was
not available until the mid 20th century when it was discovered that diethylcarbamazine
(DEC) showed remarkable effects in the treatment of Litomosoides carinii (now L.
sigmodontis, a filarial nematode that infects cotton rats) and Dirofilaria immitis (a filarial
nematode that infects dogs), and was able to clear W. bancrofti Mf from the blood of
infected humans (11-13). Ivermectin (IMV) was introduced in 1982 as a treatment for
onchocerciasis (14), and the use of this drug was expanded for the use in W. bancrofti
infected individuals just a few years later (15). In 1995 it was discovered that coadministration of both DEC and IVM together was significantly more effective than
either drug on its own (16). Finally, in 1997-1998 the third main anti-filarial drug,
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albendazole (ALB), was discovered to increase the efficacy of DEC and IVM when
added to either drug, and administered as a two-drug combination treatment (17-19). In
2000 the World Health Organization (WHO) launched the Global Program to Eliminate
LF (GPELF) (20).

1.1.3 Life cycle.
The W. bancrofti lifecycle is depicted in Figure 1.2, and it is representative of all
the LF-causing filarial nematodes, as their lifecycles are very similar. The LF-causing
filarial nematodes are vector-born, and are transmitted by mosquitos from a number of
genera (including Culex, Anopheles, Mansonia, Ochlerotatus, Coquillettidia and Aedes)
depending on the geographical location (21). The 4-8 cm long adult parasites live in the
lymphatic vessels of the human host, and the females release first stage larvae (L1)
commonly called microfilariae (Mf) into the blood (1). A single adult female worm can
release up to 10,000 Mf per day (22), and they measure approximately 260 x 8 um (1).
The lifespan of Mf is thought to be around one year (23). The Mf circulate in the blood of
infected individuals, where they have an interesting periodicity. W. bancrofti Mf are
usually most abundant in the circulation during the night (nocturnal periodicity) when the
vector mosquito typically takes blood meals from the host, whereas they sequester in the
deep vascular beds during the day (1). The Mf are ingested by female mosquitos when
the mosquito feeds on an infected human host. The Mf then migrate to the thoracic
muscle of the mosquito, where they undergo two molts (from L1 to L2 and from L2 to
L3) to become the infective third-stage larvae (L3). The larval development in the
mosquito takes a minimum of 10-12 days. Mature L3 migrate to the mouthparts of the
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mosquito where they can initiate new infections when they are transferred to humans
with the mosquito’s next blood meal. Infective larvae migrate to lymphatic vessels in the
human and grow to develop into mature adult worms over a period of several months. If
both male and female worms parasitize the same host they will reproduce, and the
females will start producing Mf, and the cycle can continue (1). The reproductive life
span of lymphatic filarial parasites is an average 4 to 6 years.
1.1.4 Wolbachia endobacteria of filarial nematodes.
Wolbachia are intracellular endosymbiotic bacteria that infect insects and
nematodes. The Wolbachia genus belongs to the family Anaplasmataceae and the order
Rickettsiales (alphaproteobacteria). There is a single species in the Wolbachia genus:
Wolbachia pipientis (24). Wolbachia was discovered to be an essential endosymbiont of
most filarial worms in 1999 (25). Many filarial nematodes, such as the lymphatic filariae
(W. bancrofti and the Brugia species) (26) and Onchocerca volvulus (causes
onchocerciasis) (27) are dependent on the Wolbachia endosymbiont for development,
fertility and survival, and the bacteria are maternally inherited (28). However, Wolbachia
is absent from Loa loa (29), the rodent filaria Acanthocheilonema viteae (30), the deer
parasite Onchocerca flexuosa (31) and many other species that infect wildlife (32). In W.
bancrofti and the brugian species of filarial nematodes, Wolbachia are present in all
developmental stages, with low amounts in the vector stages and increased amounts in
the mammalian stages (30, 33-35). In adult worms Wolbachia localizes near the
reproductive system and lateral cords, whereas it is absent from the nervous system,
digestive system and the muscles (Figure 1.3).
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1.2

Lymphatic filariasis disease and treatment.

1.2.1 Filarial disease manifestations.
LF and the host’s inflammatory response to the parasite can lead to severe
morbidity and disability with lymphedema, hydrocele, and elephantiasis (Figure 1.4). LF
is considered to be the second most common cause of long-term disability worldwide
after mental illness (19, 36). The clinical manifestations of LF range from subclinical to
pronounced chronic disease causing severe disability. Most individuals infected with LFcausing parasites have no clinical symptoms, even though Mf are present in their blood
(37). Acute manifestations of LF include acute filarial lymphangitis (AFL) and acute
dermatolymphangioadenitis (ADLA). AFL is thought to be induced by the death of adult
parasites, and it presents as acute inflammation of a lymphatic vessel. ADLA, on the
other hand, is caused by a secondary bacterial infection and is often associated with a
history of injury to the skin. ADLA typically causes severe pain, fever and chills (38, 39).
Recurrent acute attacks represent major risk factors for the development of
chronic disease manifestations. It was estimated that approximately 40 million
individuals live with symptoms of chronic LF, and this includes an estimated 25 million
men with hydroceles and an estimated 15 million individuals with lymphedema or
elephantiasis (22). Hydroceles (Figure 1.4A) are the most common chronic presentations
of LF, and they are caused by the accumulation of lymph fluid in the tunica vaginalis of
the scrotal sac, in addition to possible thickening of the spermatic cord and changes in the
skin and subcutaneous tissue around the scrotum (40). Filarial hydroceles can have a
severe negative impact on health and result in stigmatization of the affected men (41-43).
Chronic lymphedema is another common manifestation of filarial disease, and it typically
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affects the lower legs (Figure 1.4B). Adult parasites reside in the lymphatic system and
can therefore cause damage to this system. Although live worms do not induce strong
inflammatory responses, granulomatous reactions occur around dying worms (44, 45),
and this can lead to lymphatic damage. Over time the edema worsens, and it can progress
to elephantiasis (Figure 1.4C/D), which is characterized by deep skin folds and skin
fissuring that can provide pathways for entry of microorganisms (46). These secondary
bacterial and fungal infections can in turn accelerate disease progression and worsen
symptoms. Lymphedema and elephantiasis also have severe negative impacts on the
afflicted individuals and their caretakers (47).

1.2.2 Immune response during lymphatic filariasis infection.
Helminths differ from other types of pathogens because they are multicellular,
typically do not reproduce within the host, are highly motile, and often parasitize the host
for many years. Helminth infections therefore induce distinct types of immune responses.
Other microorganisms such as bacteria and viruses normally elicit a pro-inflammatory
Th1 immune response, whereas the anti-inflammatory Th2 response usually dominates in
helminth infections. The typical host immune response seen in human filarial infections
involves the production of cytokines: IL-4, IL-5, IL-9, IL-10 and IL-13; the antibody
isotypes IgG1, IgG4 and IgE; and expanded populations of eosinophils and
immunoregulatory monocytes (48). One study concluded that filarial infections are
associated with decreased parasite specific Th1 responses, such as decreased IL-2 and
IFN-γ, but normal or increased levels of parasite antigen-specific Th2 cytokines, such as
IL-4, IL-5 and IL-10 (49). Various studies have compared the cytokine profiles in the
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following clinical groups of filariasis patients: asymptomatic filarial-infected patients
(INF), individuals with chronic lymphatic obstruction (CP), and endemic normals with no
circulating Mf (EN). In a study from 1997, peripheral blood mononuclear cells (PBMCs)
were isolated from patients in the different clinical categories, and stimulated with filarial
antigens (50). This study concluded that cytokine profiles of PBMCs were different
between these categorized clinical groups, with INF PBMCs expressing elevated Th2
type cytokines like IL-4, IL-5 and IL-10 and decreased levels of IL-2 and IFN-γ in
response to parasite antigen, whereas CP individuals produced elevated levels of both
Th1 and Th2 type cytokines in response to parasite antigen. It is hypothesized that proinflammatory immune responses are responsible for the symptoms observed in CP
patients. However, most individuals infected with LF are asymptomatic, and it is believed
that a Th2 dominant response allows the immune system to tolerate the infection without
establishing a symptom-producing pro-inflammatory environment. In a review from
2001, Allen et al. suggests the following scenario: Live filarial parasites secrete
immunomodulatory molecules that induce Th2 responses, whereas dead parasites release
different substances for example from intracellular Wolbachia, leading to the activation
of macrophages with the production of pro-inflammatory cytokines and a Th1 type
response. As more parasites die the balance shifts from a Th2 response to a Th1 response
producing the symptoms of chronic filarial infections (51). Using this model to consider
what happens after anti-filarial treatment one could hypothesize that microfilariacidal
drugs, such as IVM and DEC, would result in an immediate shift from a Th2 to a Th1
response due to the huge number of dead or dying Mf.
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1.2.3 Treatment of lymphatic filariasis.
The World Health Organization (WHO) launched the Global Program to
Eliminate LF (GPELF) in 2000 with the goal of eliminating LF as a public health
problem by 2020 (2). To reach this goal, mass drug administration (MDA) programs have
been implemented in 61 countries across the world, and approximately 6 billion doses of
anti-filarial medications have been distributed, making GPELF the largest public health
intervention to date based on MDA (Figure 1.5) (3, 52). Historically, LF was treated with
a 12-day course of DEC (19). The current treatments used in LF MDA programs include
annual distribution of two-drug regimens: IVM (150 µg/kg) plus ALB (400 mg) in areas
co-endemic for onchocerciasis, or DEC (6 mg/kg) plus ALB (400 mg) in the rest of the
world. Exceptions to the two-drug regimens include areas that are co-endemic for L. loa
where only ALB can be safely used (400 mg. ALB preferably twice a year), and the new
triple therapy (“IDA”, discussed below). LF MDA programs have been successful in
decreasing LF infection parameters such as microfilaremia (Mf present in the blood),
filarial antigenemia and anti-filarial antibody rates in treated populations (53). The
implementation of MDA is based on community diagnosis to identify endemic areas
followed by distribution of anti-filarial medications annually for 5-8 years to entire at-risk
populations. There is a clear correlation between the number of completed treatment
rounds and infection clearance (54). The GPELF strategy has been shown to be feasible
and cost-effective (55, 56), in large part because the drugs are donated by pharmaceutical
partners.
A new and exciting breakthrough in the field of LF treatment was the discovery
that co-administration of all three anti-filarial drugs, IVM, DEC and ALB (sometimes
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referred to as IDA), had increased efficacy against LF. The first study was conducted in
Papua New Guinea and published in 2016 (57). In this pilot study the efficacy, safety,
and pharmacokinetics of single-dose IVM, DEC and ALB was tested in W. bancroftiinfected adults. Twelve individuals were treated with the new triple therapy and twelve
individuals were treated with the standard LF treatment for Papua New Guinea (DEC
plus ALB). The results were surprisingly impressive as all 12 individuals who received
the triple therapy were Mf negative one year post-treatment, whereas only 1 of 12
individuals treated with standard double therapy were Mf negative at one year posttreatment (57). Larger clinical trials to test the efficacy of the triple therapy are underway
in Papua New Guinea (Clinicaltrials.gov NCT # 01975441) and Côte d'Ivoire
(Clinicaltrials.gov NCT # 02974049), and the new data appears to confirm the finding
that IDA is more effective than the standard LF treatment regimens (58, 59). The safety
of the triple therapy treatment is currently being evaluated in large community-based
studies in India, Indonesia, Haiti, Papua New Guinea and Fiji, where over 10,000
individuals have been treated with IDA (ClinicalTrials.gov Identifier: NCT02899936).
Based on this extensive safety data, the WHO recently recommended IDA as the
preferred treatment for certain LF endemic areas (60).

1.2.4 Mechanism of action of the anti-filarial drugs.
ALB binds to nematode tubulin thereby inhibiting polymerization and the
assembly into microtubules. This causes degenerative changes in the tegument and
intestinal cells of the parasite, which results in impaired uptake of glucose, and the
glycogen stores in the parasite are depleted (61). The degenerative alterations also result
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in decreased production of adenosine triphosphate by the parasite, which is an important
source of energy required for survival. Ultimately the parasite is immobilized because of
this diminished energy production, and it eventually dies.
DEC is an antifilarial drug that is structurally dissimilar from ALB and IVM, and
it has been used in the treatment of LF since 1947. DEC inhibits arachidonic acid
metabolism and inducible nitric oxide synthase (62). The mode of action by which DEC
kills LF parasites is still poorly understood. It is particularly remarkable that DEC exerts
its anti-filarial effects within minutes in vivo with decreasing Mf counts, but it has
virtually no effect on Mf in vitro (63). This indicates that DEC requires host factors for
its activity, and previous work has suggested that the innate immune system is involved
(64). DEC decreases circulating Mf within days of treatment, and is also believed to have
some macrofilaricidal effect (65).
IVM is an avermectin compound that was initially derived from the bacterium
Streptomyces avermitilis (66). Similar to DEC, IVM has little effect on filarial parasites
in vitro (67), and it has been shown to interact with the host immune system (68). The
mode of action by which IVM kills Mf is not completely delineated, but it interferes with
glutamate-gated ion channels that can affect parasite contractility and release of
immunomodulatory molecules (68). The parasite’s nervous system and muscular system
is also affected by IVM.
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1.3

Adverse events after anti-filarial treatment.

1.3.1 Overview and impact of adverse events.
The medications used for LF MDA; ALB, IVM and DEC, have well-established
safety profiles, and severe adverse events are extremely rare (69-72). However, mild to
moderate adverse events (AEs), such as fever, myalgia, headache and hypotension, are
common in LF-infected individuals (2, 61, 71). The fear of AEs in communities receiving
MDA is a main factor that reduces compliance (73, 74). Minimizing the impact of AEs
has therefore been identified as a key component for successful MDA programs (73).
Prior studies have shown that AEs are almost exclusively observed in people with
microfilaremia, and the severity of AEs is strongly correlated with Mf counts (75, 76).
Uninfected individuals very rarely experience AEs after LF MDA (77), so the AEs
experienced by LF-infected individuals are not a result of direct drug toxicity. These
observations have led to the hypothesis that AEs are caused by immune responses to dead
or dying Mf and adult worms.
In contrary to the mild and moderate AEs observed when DEC and IVM are
administered to LF-infected individuals, both of these drugs can cause severe AEs
including encephalopathy and death when used in individuals infected with L. loa, that
can exhibit very high Mf levels (78, 79). Additionally, DEC can result in loss of vision
and other severe eye damage if administered to individuals infected with O. volvulus (80,
81). DEC is therefore not used in areas in Africa where LF is co-endemic with O.
volvulus or L. loa. IVM is not used in areas that are co-endemic for L. loa, unless it is
meso or hyperendemic for O. volvulus in which case the risk of blindness caused by
onchocerciasis outweighs the risk of AEs caused by IVM treatment.
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1.3.2 Host responses and adverse events following treatment of LF.
Only a few studies have examined cytokine changes following anti-filarial
treatment, and the majority of these studies are older and therefore used the then
recommended, but now outdated, treatment for LF, a multiday course of DEC. IL-5 has
been shown to increase in sera from patients infected with W. bancrofti immediately
following DEC treatment (82, 83) leading to a transient decrease in peripheral
eosinophils as they migrate to the tissue, followed by peripheral eosinophilia at 4-6 days
post-treatment (82). IL-5 has not been linked to AEs following treatment. However, other
cytokines have been shown to increase after anti-filarial treatment, and have been
implicated in the development of AEs. A study from 1994 collected plasma from 10 W.
bancrofti-infected men immediately before and 2 and 6 hours after the first dose of a
multiday DEC treatment, and measured IL-6 and TNF-α levels in the plasma. They found
both IL-6 and TNF-α were increased in plasma collected from the 5 individuals with AEs
post-treatment (84). Another study also found a strong correlation between inflammatory
mediators and the severity of AEs following treatment. In this study from 2000 they used
ELISAs to measure various cytokine levels before and after a 12-day treatment with daily
doses of DEC in 29 B. malayi infected individuals. They found that increased posttreatment levels of IL-6, lipopolysaccharide binding protein (LBP), IL-10 and soluble
TNF receptors (sTNF-R) were correlated with systemic reactions after DEC treatment of
filarial patients, with the strongest association being with IL-6 and LBP. In this study
post-treatment blood was collected at 2, 4, 8, 24, 32, 48 and 120 hours after the initial
DEC dose, and IL-6 levels peaked between 8-24 hours whereas LBP levels peaked
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between 24-48 hours (85). AEs after anti-filarial treatment peak at around 24-48 hours
post-treatment (75, 86-89). In agreement with these result another study concluded that
IL-6, but not TNF- α was correlated with AEs, and peaked at 24 hours post-treatment;
however only four B. malayi infected individuals were included in that study (87). A
single published study found no correlation between IL-6 and AEs following a single
dose of DEC in a cohort of 47 W. bancrofti-infected men in Tanzania. All study
participants developed AEs, but the research group found no correlation between severity
of AEs and IL-6 levels post-treatment (90). Increased post-treatment levels of IL-6 have
also been associated with the development of AEs in onchocerciasis patients after
treatment (84, 91). All the previously published studies that focused on AEs after LFtreatment had small sample sizes, and they used the standard of care for their time,
instead of the current WHO recommended treatments for LF.

1.3.3 Wolbachia as a cause of adverse events.
Wolbachia has been hypothesized to be involved in the development of posttreatment AEs in LF-infected individuals since its re-discovery in these parasites in 1999.
A popular hypothesis to explain AEs is that the Wolbachia endosymbiont are released
from dying filarial worms and Mf after treatment, and that this is the main cause of AEs.
A study that supports this scenario measured Wolbachia DNA in human plasma before
and after treatment in B. malayi infected adults treated daily for 12 days with DEC. Posttreatment blood was collected at 2, 4, 8, 24, 32, 48 and 120 hours after the first dose, and
it was concluded that people with moderate and severe AEs had more Wolbachia positive
post-treatment samples when compared to people with mild or no AEs. This study also
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concluded that the DNA was from whole bacterial cells and not free DNA, because after
the plasma was centrifuged Wolbachia DNA was only detected in the pellet (92).
A more detailed model for how Wolbachia induces AEs was introduced by Taylor
et al. in two papers from 2000-2001, where the authors state that Wolbachia can release
LPS-like molecules that activate the innate inflammatory response through toll like
receptors (TLRs) leading to either the symptoms of chronic infections or the AEs
following treatment (Figure 1.6) (93, 94). This hypothesis was based on the discovery of
a B. malayi derived LPS-like molecule that was heat-stable, reacted positively in the
Limulus amoebocyte lysate (LAL) assay, and could be inhibited by polymyxin B. This
soluble extract is a potent inducer of TNF- α, IL-1β and nitric oxide (NO) in murine
macrophages. B. malayi extract cannot induce these cytokines in macrophages from LPSnonresponsive C3H/HeJ mice (TLR4 defective due to mutation), suggesting that
signaling occurs through TLR4. Additionally, extracts from the filarial worm A. viteae
(no Wolbachia) do not elicit this pro-inflammatory response in macrophages, and did not
react positively in the LAL assay, indicating that the LPS-like molecule in the B. malayi
extracts originated from Wolbachia. Live filarial parasites and culture supernatants failed
to elicit inflammatory responses from macrophages, so they hypothesized that the
Wolbachia substrate is only released from dying worms. The Taylor group later revised
their initial hypothesis and replaced TLR4 with TLR2-TLR6 in their proposed Wolbachia
LPS-like signaling pathway (95). In this publication they used cell lines transfected with
human TLRs and macrophages from TLR and adapter molecule deficient mice, and
observed TLR2-TLR6 activation by the Wolbachia LPS-like molecule utilizing the
mediators MyD88 and TIRAP/Mal. From the literature it is known that TLR2 can bind
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bacterial lipoproteins, LPS and other bacterial components and activate NF-κB that in
turn induces pro-inflammatory cytokines such as IL-6 (96, 97).
Interestingly, the B. malayi-associated Wolbachia genome was published in 20042005 (98, 99), and it did not include the homologs of the genes responsible for the
biosynthesis of lipid A (a component of LPS). It is therefore unlikely that B. malayi
Wolbachia contains LPS in its cell wall (99). However, the published Wolbachia genome
and bioinformatics methods have been used to predict the presence of two putative
candidate Wolbachia lipoproteins: peptidoglycan-associated lipoprotein (PAL), and a
type IV secretion system protein (VirB6) (100). In this same publication Turner et al.
conclude that a synthetic, lipolated version of the N-terminus of Wolbachia PAL, WoLP,
can signal through TLR2-TLR6, and induce pro-inflammatory responses in vitro (murine
and human cells) and in vivo (mice). In a 2014 publication, Tamarozzi et al. conclude that
WoLP can activate human neutrophils in vitro as shown by changes in their cell shape
and IL-8 production upon exposure to this stimulus (101). Recently a proteomics
approach has confirmed the presence of PAL in extracts of B. malayi, and it was one of
the most abundant proteins found in extracts from adult female worms. Additionally
immunogold labeling showed that the lipoprotein was localized in the bacterial
membrane (102). There is still insufficient evidence in vivo to show that endosymbiotic
bacteria provide a pro-inflammatory stimulus, and there is no information about levels of
this lipoprotein/LPS-like substance is post-treatment plasma of LF-infected individuals.
The major surface protein of Wolbachia (WSP) has also been identified to
activate the innate immune response through TLR signaling (103). In this study, cultured
whole blood cells from O. volvulus infected individuals were stimulated with purified
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recombinant WSP, and found to release TNF-α, IL-12 and IL-8 in response to
stimulation. These results were confirmed in PMBCs isolated from 3 healthy Europeans,
where rWSP strongly stimulated the release of TNF-α, IL-1β, IL-6, and IL-8. This
immune response was dependent on TLR2 and TLR4. WSP has been shown to be
antigenic, and WSP-specific antibodies have been identified in human sera from infected
individuals, with CP patients having the highest level of antibodies (104).
In a study from 2008 Supali et al. demonstrated that a six-week treatment course
of doxycycline before DEC/ALB anti-filarial treatment decreased the risk of AEs (105).
This was a double-blind, randomized, placebo-controlled field trial of 161 B. malayi
infected persons. After the doxycycline treatment the Wolbachia load was decreased by
98%, and AEs following DEC/ALB were less in the group that received pre-treatment
doxycycline when compared to those who received pre-treatment placebo. However, at
the one-year follow-up microfilaremia was reduced by 87.5% in patients receiving both
doxycycline and DEC/ALB, but only 26.7% in individuals receiving only DEC/ALB, so
it is unclear if the decrease in AEs was due to decreased Mf loads or decreased
Wolbachia after the doxycycline treatment.
An onchocerciasis mouse model has been used to study the role of Wolbachia in
eliciting pro-inflammatory pathways causing corneal inflammatory pathology (106). In
this study various filarial worm extracts were injected into the murine corneal stroma, and
the resulting pathology scored. It was concluded that extracts from doxycycline treated
worms (decreased Wolbachia) induced less pathology in the cornea when compared to
non-treated worm extracts. The group also concluded that Wolbachia containing extracts
from B. malayi resulted in more inflammation when compared to A. viteae extracts.
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Finally, the LPS-hyporesponsive C3H/HeJ mice demonstrated less pathology indicating
signaling through TLR4. The previously mentioned WoLP has also been shown to induce
corneal inflammation using this model (100).
It is difficult to attribute all AEs following anti-filarial treatment to Wolbachia. L.
loa is a Wolbachia-free filarial nematode that infects humans, and it is responsible for the
most severe post-treatment AEs observed after LF MDA. Individuals with high L. loa
infection burdens can develop encephalopathy and die after IVM treatment, and this is
not observed in LF patients (79). A group has reported that rodents infected with A.
viteae develop severe AEs and die following effective microfilaricidal therapy, whereas
animals infected with the Wolbachia-containing B. malayi tolerate corresponding
treatment (107). They conclude that AEs might be caused by Mf-derived components
different from Wolbachia-released factors.

1.3.4 Circulating immune complexes as a cause of adverse events.
Immune complexes (IC) are heterogeneous high molecular-weight aggregates of
antigens, antibodies and components of the complement cascade (108), and when they
circulate or accumulate in tissue they activate pro-inflammatory pathways. A paper from
1991 hypothesized that AEs following DEC or IVM treatment could be caused by
immune complexes triggered by the release of filarial antigens following treatment (109).
In this double-blind study 60 patients infected with W. bancrofti were randomized to
receive a 14-day treatment of DEC or a single dose of IVM, and various immunological
changes were followed after treatment. The results show that 24-48 hours after treatment
antibodies to microfilarial excretory-secretory (ES) antigens decreased, with a concurrent
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increase in filarial HC 11 antigens (HC 11 is a phosphorylcholine determinant present in
all filarial worm stages), and these changes were temporally associated with the onset of
AEs. The authors reported that the serological changes occurred in the majority of
patients, but the magnitude was significantly greater in individuals who developed AEs.
It is possible that the results might have been more significant and different earlier, if the
data had been analyzed using only individuals with AEs.
A study from 1988 also concluded that filarial ES antigen titer increased after DEC
treatment, and this group additionally observed an increase in IC titer after treatment
(110). In this study 27 W. bancrofti-infected patients were treated for 12 days with DEC,
and blood was collected before and 7 days after the first DEC dose. An anti C3 ELISA
was used to measure ICs. The mean ES antigen titers increased from 732 to 1633 on day
7, whereas filarial-specific IgG and IgM antibody levels decreased during this time. Only
3 individuals had detectable filarial IC before treatment, but a sudden increase of mean
IC titer of 73,020 at day 7 was observed in these individuals.
More recently Senbagavalli et al. hypothesized that the interaction of circulating
immune complexes (CIC) and complement with the host innate immune system is a
major contributing factor in the development of lymphatic pathological change and/or
host resistance (111). In this paper from 2011 the authors determined the levels of CIC in
the different clinical categories of LF (INF, CP and EN) in a total of 120 individuals.
CICs were assayed by using a polyethylene glycol (PEG) precipitation method and an
enzyme immunoassay (EIA), and irrespective of the method used INF had significantly
(P < 0.001) higher levels of CIC than either CP or EN. This result contradicts previously
published data that reports highest levels of CIC in CP individuals (112). This paper also
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describes how cultured granulocytes from healthy controls respond by cytokine release
when stimulated with PEG-precipitated IC from INF, CP and EN plasma. IC from INF
and CP induced significantly higher levels of IL-6 and IL-17 when compared to EN. In
contrast to the pro-inflammatory cytokines, IL-4, was reduced when granulocytes were
incubated with IC from INF and CP compared to EN. No significant difference was
found for other cytokines, such as TNF-α, IL-1β and IL-10.

1.3.5 Host gene expression before and after treatment in lymphatic filariasis patients.
There are no published human RNA sequencing data for LF infections. Semnani
et al. used microarrays to examine the effect of treatment on gene expression in
monocytes from LF patients (113). PBMCs were isolated from 4 W. bancrofti-infected
individuals before treatment and at 8 months after IVM/ALB treatment. The results
showed that 47 genes were repressed and 41 genes were induced in paired samples (preversus post-treatment). Utilizing hierarchical clustering they identified distinct sets of
genes that were highly expressed pre-treatment and repressed post-treatment, and
opposite. Genes induced post-treatment included many members of the heat shock
protein (HSP) family with ATP binding activity, and genes involved in signal
transduction, such as IL-1 receptor type I. Among the genes repressed in the posttreatment samples were those involved in signaling (chemokine receptor 7, mitogenactivated protein kinase 8, Epstein-Barr virus-induced gene 2), transcription and protein
metabolism. Interestingly, this study also examined the difference in gene expression
between monocytes from LF infected and un-infected individuals. Only 62 genes (8
repressed and 54 induced in W. bancrofti-infected individuals) out of the possible 30,000
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were significantly different in monocytes of W. bancrofti-infected versus W. bancroftiuninfected individuals. The genes over-expressed in LF patients were involved in
apoptosis (IL-1β, BCL2A1, and MOAP1) and cell adhesion. Treatment with single-dose
IVM plus ALB normalized monocyte gene expression at 8 months. Host gene expression
has not been correlated to the development of AEs after treatment for LF.

1.4

Obstacles and resources for studying adverse events after anti-filarial treatment.

1.4.1 Obstacles.
In vitro culture systems and convenient animal models are not available for the
most clinically relevant and important filarial nematodes, W. bancrofti and O. volvulus.
B. malayi and the Wolbachia-free A. viteae, on the other hand, can be maintained in the
laboratory in gerbils (114-116). The filarial nematode Litomosoides sigmondontis
normally infects cotton rats, but it can also be maintained in a mouse model (116). Even
with these possible model systems, studying AEs in an animal model would be very
complex. The drugs that cause AEs (IVM and DEC) only exert their anti-filarial effects
in vivo when they can work with the host immune system. It is unclear how mouse or
gerbil immune systems differ in regards to treatment efficacy and AE rates and
presentation. Another problem would be how to measure AEs in the animal. Therefore, in
my thesis I focus only on the study of AE pathogenesis in humans, and this approach of
course has its own limitations. It is impossible to control for all possible variables in a
human sample set. For example, gene expression can be influenced by age, sex, diet,
season, general health status and a wealth of other factors. In order to minimize these
confounding variables as much as possible, we decided to look at the change in gene

22

expression (and filarial components) in the same individuals just before treatment and at
24 hours post-treatment. This short 24-hour timeframe minimizes the effects of other
variables; therefore treatment and/or the development of AEs is the main factor that
influences the change in gene expression during this time. We also collected as much
information as possible for each individual including detailed clinical data, so a metadata
analysis could be completed.

1.4.2 Resources.
The most crucial stage of this project was to collect appropriate human samples in
order to test our hypotheses. Our group is spearheading the broad research project Death
to Onchocerciasis and Lymphatic Filariasis (DOLF, www.dolf.wustl.edu). DOLF is
currently involved in clinical and community trials in over ten LF-endemic countries, and
this has allowed me to access valuable human samples and clinical data. Additionally,
our group has developed a long-lasting collaboration with Dr. Mitreva’s group at the
McDonnell Genome Institute (MGI) at Washington University, which has been
invaluable during the analysis stage for the complex RNA-seq data.

1.5

Aims and scope of thesis.
It is well established that AEs occur commonly in LF-infected individuals after
treatment, but the pathogenesis is still not completely understood. State of the art
comprehensive studies that considered both filarial and host involvement in AE
development were lacking. In this study we therefore examined the possible immunestimulatory filarial components that are released post-treatment, and the host immune
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response during AEs. The objective of this thesis was to characterize the host response
during post-treatment AEs, and to identify possible parasite components that trigger AEs.
We hypothesized that AEs are associated with unique host response patterns, and that
filarial and/or Wolbachia components are released post-treatment and these foreign
antigens and/or CIC can trigger AEs.
The fear of AEs after treatment is an important factor leads to non-compliance
with LF MDA programs. Understanding the underlying mechanisms for the development
of AEs can help to improve management, and increase the compliance to MDA
programs, and this can have a positive impact on millions of LF infected people that will
be treated over the next many years. This will be particularly important for the new triple
therapy, because this treatment might become more mainstream within the next years.
We will therefore be on the forefront with innovative and relevant data on the
pathogenesis of AEs related to this treatment. This data will be very important because in
the preliminary studies over 50% of LF of infected individuals that received the triple
therapy developed AEs (57).
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Figure 1.1: Historical background of lymphatic filariasis.
[A] Ancient Egyptian relief possibly depicting elephantiasis from 1500 B.C. This image is
available on the Encyclopedia Britannica website (https://www.britannica.com/place/Punthistorical-region-Africa). [B] A West African Nok sculpture from 500 B.C. portraying a man
with a hydrocele. This image is available at
http://www.invivo.fiocruz.br/cgi/cgilua.exe/sys/start.htm?UserActiveTemplate=english&infoid=
1113&sid=45.
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Figure 1.2: Life cycle of Wuchereria bancrofti.
This figure is available on the Centers for Disease Control and Prevention website
(https://www.cdc.gov/parasites/lymphaticfilariasis/biology_w_bancrofti.html).
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Figure 1.3: Distribution of Wolbachia endosymbionts in adult filarial worms.
Longitudinal cross-section of mature [A] and immature [B] adult female filarial worm with
Wolbachia highlighted as red dots. [C] Longitudinal cross-section of mature adult male filarial
worm with Wolbachia highlighted as red dots.
Figure and text adapted from Fischer K, Beatty WL, Jiang D, Weil GJ, and Fischer PU. Tissue
and stage-specific distribution of Wolbachia in Brugia malayi. PLoS Negl Trop Dis.
2011;5(5):e1174.
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Figure 1.4: Images of clinical manifestations of lymphatic filariasis.
[A] Hydrocele in a patient from Cote d’Ivoire. [B] Advanced lymphedema in a patient from Alor
Island, Indonesia. [C and D] Elephantiasis of the leg. [C] shows a lower leg of a woman in Sri
Lanka and [D] shows scientists inspecting deep skin folds in a patient from central Java,
Indonesia. Photos were provided by Peter U. Fischer and Gary J. Weil.
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Figure 1.5: The progress of GPELF (Global Program to Eliminate Lymphatic Filariasis).
[A] The cumulative number of countries that have started an LF mass drug administration
control program from the year 2000 to 2014. [B] The cumulative number of anti-LF treatments
delivered by GPELF from the year 2000 to 2014. Data is from the World Health Organization’s
(WHO) PCT databank (Lymphatic filariasis), and the values in black represent the data that was
not included in the previous published analyses (55, 117). Insert in [B] represents the proportion
of the treatments delivered to each of the WHO regions (AMRO: Region of the Americas, AFRO:
African Region, EMRO: Eastern Mediterranean Region, WPRO: Western Pacific Region, and
SEARO: South-East Asia Region).
Figure and text adapted from Turner HC, Bettis AA, Chu BK, McFarland DA, Hooper PJ,
Ottesen EA, and Bradley MH. The health and economic benefits of the global program to
eliminate lymphatic filariasis (2000-2014). Infect Dis Poverty. 2016;5(1):54.
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Figure 1.6: Wolbachia signaling pathway.
An overview of the proposed mechanisms by which Wolbachia contributes to the pathogenesis
of lymphatic filarial disease and adverse events after treatment.
Figure is adapted from Taylor MJ, Cross HF, Ford L, Makunde WH, Prasad GB, and Bilo K.
Wolbachia bacteria in filarial immunity and disease. Parasite Immunol. 2001;23(7):401-9.
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Chapter 2:
Changes in cytokine, filarial antigen, and DNA levels associated
with adverse events following treatment of lymphatic filariasis
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2.1

Summary.
Background: Mild to moderate adverse events (AEs) are common after treatment
of lymphatic filariasis (LF) and pose a major challenge for the global LF elimination
program. We studied changes in cytokine levels and filarial worm components in plasma
of subjects with and without AEs following treatment of LF.
Methods: Participants (N=24) were hospitalized and monitored for AEs following
treatment. Cytokines (27), filarial DNA, circulating filarial antigen (CFA), and immune
complexes were measured in plasma samples collected before and after treatment.
Results: Levels for 16 cytokines increased after treatment in individuals with
moderate AEs compared to individuals with no and/or mild AEs. These included three
major pro-inflammatory cytokines (IL-6, TNF-α and IL-1β). Eotaxin-1 levels were
elevated at baseline in individuals who developed moderate AEs after treatment; thus
eotaxin-1 is a potential biomarker for AE risk. CFA and filarial DNA levels increased
more in individuals with moderate AEs after treatment than in people with no/mild AEs.
Conclusions: Increases in cytokine, filarial DNA and CFA levels were associated
with development of AEs following treatment of LF. Improved understanding of the
pathogenesis of AEs may lead to improved methods for their prevention or management
that could increase compliance in elimination programs.
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2.2 Introduction.
Lymphatic filariasis (LF) is a neglected tropical disease that is caused by the nematode
parasites Wuchereria bancrofti, Brugia malayi and B. timori. Adult worms release first stage
larvae (microfilariae or Mf) into the blood, and these are ingested by mosquitoes. The
parasites develop to become infective third stage larvae that can initiate new infections when
they are transmitted to humans by mosquitoes. The worms and the host’s inflammatory
responses can lead to severe morbidity with lymphedema, hydrocele, and elephantiasis (1).
The World Health Organization (WHO) launched the Global Program to Eliminate LF
(GPELF) in the year 2000 with the goal of eliminating LF as a public health problem by
2020. The primary tool used by GPELF is annual mass drug administration (MDA), and
some 500 million people are treated each year (2). The medications used, namely
albendazole (ALB), ivermectin (IVM) and diethylcarbamazine (DEC), have well-established
safety profiles, and serious adverse events (AEs) related to treatment are very rare. However,
mild to moderate AEs such as fever, and headache are common. High MDA compliance is
important for LF elimination programs (3). The fear of AEs in communities receiving MDA
reduces compliance (4, 5). Understanding the pathogenesis AEs is even more urgent at this
time, because recent studies have shown that a single dose of all three LF MDA drugs (IVM,
DEC and ALB, sometimes called “IDA”) is more effective for clearing Mf than the current
two-drug MDA regimens ((6) and authors’ unpublished observations). This increased
efficacy may be associated with increased AE rates in infected individuals.
The pathogenesis of AEs after treatment of LF is poorly understood. Host immune
responses and parasite death are believed to be involved, because post-treatment AE rates are
much higher in infected individuals, and because AE rates are correlated with blood Mf
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counts (7). AEs are probably related to release of parasite antigens and/or Wolbachia (an
intracellular alpha proteobacteria found in LF-causing filarial worms). Wolbachia-derived
molecules may interact directly with the innate immune system through ligands such as Tolllike receptors (TLRs) to activate immune cells to release cytokines (8-13). Few studies have
looked at changes in cytokines associated with AEs following LF treatment. One study
documented increases in IL-6 and TNF-α after treatment in five men with AEs (14). Another
study reported that AEs were associated with increased levels of IL-6, lipopolysaccharide
binding protein (LBP), IL-10 and soluble TNF receptor (15). Other studies suggested that
AEs may be related to circulating immune complexes (CIC) that form when filarial antigens
are released by dying parasites (16, 17). CIC from plasma of LF-infected individuals have
been shown to be pro-inflammatory when added to granulocytes (18). A recent clinical trial
provided us with the opportunity to use 21st century methods to revisit the issue of AE
pathogenesis.

2.3

Methods.
Study design.
Plasma samples used for this study were obtained during a pharmacokinetic trial
conducted in Papua New Guinea (PNG) in 2013 (6). Twenty-four W. bancrofti infected
individuals were randomized to one of two treatment arms: the standard LF MDA
regimen for PNG (ALB and DEC) or the new IDA triple therapy regimen. The AE
assessment protocol was described in a previous publication (6). Briefly, objective AEs
were assessed (vital signs and a brief physical exam) for all study participants at 0, 4, 8,
12, 24, 48 and 72 hours post-treatment in a hospital setting. Subjective AEs were
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assessed at the same times by asking the participants open-ended questions about
symptoms that developed after treatment. All participants were followed as outpatients
and examined on day 7. Nineteen of 24 participants (79%) developed at least one AE,
and 7 of these individuals had fevers greater than 38°C. Blood was collected immediately
before treatment and at 11 time-points after treatment (1hr to 72hrs). Notable in this study
was the high Mf levels (geometric mean = 1,679, range 133-13,776 Mf/mL). Plasma
samples were stored and shipped at -80°C. Informed consent was obtained from all
participants as previously described (6).

Adverse events classification.
AEs were scored as none, mild, or moderate. Those with moderate AEs (N=7) had
at least one new symptom plus objectively measured fever (a temperature of > 38°C)
within 72 hours after treatment. Individuals with subjective or objective AEs without
fever were considered to have mild AEs (N=12). Individuals with no objective or
subjective symptoms were considered to have no AEs (N=5).

Cytokine assay.
Twenty-seven cytokines were measured using a MAGPIX system with the BioPlex Human 27-Plex Cytokine Panel and Bio-Plex Cytokine Reagent Kit (Bio-Rad,
Hercules, CA). Plasma samples were thawed and centrifuged before testing. A
preliminary study tested samples from all 12 time-points (pre-treatment and 1, 2, 3, 4, 6,
8, 12, 24, 36, 48 and 72 hours post-treatment) for 7 participants. Since there were no
changes in cytokine levels during the first 6 hours, only 7 time points (pre-treatment, 8,
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12, 24, 36, 48 and 72 hours post-treatment) were tested for the remaining 17 study
participants. All samples were tested in duplicate, and all samples from the same
individual were run on the same plate. The cytokine assay panel included IL-1β, IL-1Ra,
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, basic
FGF, eotaxin-1, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-BB,
RANTES, TNF-α, and VEGF. Standard curves were calculated using the manufacturer’s
software, and our analysis considered mean concentrations (pg/mL) from two duplicate
wells. Mean levels for all 27 cytokines were calculated for each AE group at each timepoint. Kruskal-Wallis H tests were used to compare absolute cytokine levels between the
three AE groups at each time-point. Wilcoxon signed-rank tests were used to compare
post-treatment levels to baseline levels within AE groups for each time-point. After
evaluation of the data three outliers with extremely elevated levels at baseline were
excluded from the analysis.

Circulating Filarial Antigen (CFA).
A direct sandwich enzyme immunoassay (EIA) was performed as previously
described (19, 20). Plasma samples were available for 21 of the 24 individuals for this
test (6 moderate, 10 mild, and 5 no AEs), and samples from 5 time-points were tested
(pre-treatment, 6, 12, 24 and 48 hours post-treatment). All samples from individual
participants were tested in duplicate on the same plate. The mean CFA levels were
calculated for each AE group at each time-point. Kruskal-Wallis H tests were used to
compare the absolute CFA levels between the three AE groups at each time-point.
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Wilcoxon signed-rank tests were used to compare post-treatment CFA levels at each
time-point to baseline levels within the AE groups.

Detection of filarial DNA by qPCR.
DNA was extracted from 100µL of plasma using the E.Z.N.A. Tissue DNA Kit
(Omega Bio-tek, Norcross, GA) using the manufacturer’s protocol. The qPCR assay was
a TaqMan probe-based assay, and the target was the “long DNA repeat” of W. bancrofti
(LDR; GenBank accession no. AY297458). We used previously published primers and
probes (21) purchased from Integrated DNA Technologies (Coralville, IA). Real-time
PCR reactions were performed with 10µL of TaqMan master mix (Applied Biosystems,
Foster City, CA) plus 450 nmol/L of primers, 125 nmol/L probe, and 2µL DNA with a
final volume of 20µL. Thermal cycling was performed with a QuantStudio 7-Plex RealTime PCR System (Applied Biosystems). PCR reactions were carried out for 40 cycles,
and cycle threshold (Ct) values were determined using the manufacturer’s software.
Plasma samples were available for 21 of the 24 individuals for this assay (7 moderate, 9
mild, and 5 no AEs), and 7 time-points were selected (pre-treatment, 8, 12, 24, 36, 48 and
72 hours post-treatment). Samples were run in duplicate, and all samples from individual
participants were tested on the same plate. Each plate contained a positive control (DNA
extracted from W. bancrofti Mf), and two negative controls (DNA extracted from plasma
samples from healthy North American control subjects and deionized water). Delta Ct
values (baseline Ct value minus post-treatment Ct value) were calculated at each timepoint for each individual, and one-way ANOVA analysis was used to compare the delta
Ct values between the three AE groups at each time-point.
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Immune complex assay.
In this assay CIC were incubated with human C1q (part of the first component in
the classical complement pathway) that was immobilized on microtiter plates. C1q was
purchased from Sigma-Aldrich, St. Louis, MO. Nunc Immulon 2HB flat-bottom 96-well
plates (Thermo Scientific, Waltham, MA) were coated with 50µL of 0.01mg/mL C1q in
1x PBS pH7.4 and incubated at 4°C overnight. Plates were washed and blocked for 1
hour at room temperature (RT). After washing, 50µL sample plasma or standard (diluted
1:60 in PBS with 0.5% casein, 0.5% Tween-20) was added to each well, and the plates
were incubated at RT for 1 hour. Aggregated human gamma globulin (AHG) was used as
the positive control and standard. Alkaline phosphatase-conjugated goat anti-human IgG
was used at a dilution of 1:1000, and plates were incubated for 1 hour at 37°C. The plates
were developed with alkaline phosphatase substrate (pNPP disodium salt hexahydrate)
and read at 405nm. Plasma was available from 20 of the 24 individuals for this assay (7
moderate, 10 mild, and 5 no AEs), and 7 time-points were selected (pre-treatment, 8, 12,
24, 36, 48 and 72 hours post-treatment). Samples were run in duplicate and all samples
from individual participants were run on the same plate. Each plate contained two
negative controls (plasma samples from healthy North American control subjects and
deionized water). Values were expressed as ng/mL of AHG, and mean CIC values were
calculated for each AE group at each time-point. Kruskal-Wallis H tests were used to
compare absolute CIC levels between the three AE groups at each time-point. Wilcoxon
signed-rank tests were used to compare post-treatment CIC levels at each time-point to
baseline levels within each AE group.
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2.4

Results.
Cytokine levels.
Three of the 24 individuals (all in the mild AE group) had extremely elevated
cytokine levels at baseline, and they were excluded from the analysis. These three
individuals had outlier levels for 9, 12 and 14 of the 27 measured cytokines respectively,
at baseline. These high baseline cytokine levels were unrelated to treatment and their
inclusion would have distorted the data, because the aim of the study was to investigate
the change in cytokines post-treatment.
Changes in cytokine levels after treatment were significantly different in persons
with moderate AEs compared to those in persons with no and/or mild AEs for 22 of the
27 cytokines tested (Table 2.1) (Kruskal-Wallis analysis followed by post-hoc tests to
determine which AE groups were significantly different). Most of these cytokines (IL1β, IL-1Ra, IL-4, IL-6, IL-7, IL-10, IL-12, IL-17, G-CSF, IP-10, MCP-1, MIP-1α,
PDGF-BB, MIP-1β, TNF-α, and VEGF) increased significantly more in the moderate AE
group after treatment compared to the no and/or mild AE groups. IL-6, IL-10, MCP-1
and MIP-1β had the most dramatic post-treatment increases in the moderate AE group
(Figure 2.1). Several cytokines (IL-8, IL-13 and eotaxin-1) were significantly higher at
baseline in persons who developed moderate AEs. Eotaxin-1 was greatly increased pretreatment in 6 out of the 7 individuals who later developed moderate AEs (Figure 2.2).
Baseline eotaxin-1 levels were not correlated with baseline Mf counts. The finding that
some cytokines were higher at baseline in individuals who would go on to develop AEs
was surprising, and we decided to redo the analysis including the three excluded
individuals. There was still a significant difference in baseline eotaxin-1 and IL-8 levels
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between individuals with moderate AEs compared to individuals with no and/or mild
AEs. However the difference in IL-13 at baseline disappeared when the outliers were
included.
Values for several cytokines were lower at baseline (RANTES) or decreased
significantly post-treatment (IL-2 and IL-15) in people who developed moderate AEs
compared to people with no and/or mild AEs. Five cytokines (IL-5, IL-9, FGF-basic,
GM-CSF and IFN- γ) did not differ by AE group at any time-point, however IL-5 did
increase post-treatment as previously described (22, 23). We did not correct for multiple
comparisons, so additional data would be needed to confirm our findings. However, the
differences in cytokine levels were dramatic between the AE groups, and they persisted
over time making the results more credible. Based on the standard significance level of
0.05, approximately 3 differences would be expected to be significant by chance for 54
tests (27 cytokines measured at 2 time-points). We found 28 significant differences in
cytokines levels at 12 and 24 hours post-treatment.

CFA levels and Mf counts.
CFA is known to circulate in the blood of LF-infected individuals, and this
antigen is used as a diagnostic marker. The detection limit of the CFA EIA assay is
6.3ng/mL. CFA was detected in all samples from all study subjects. Baseline CFA levels
were positively correlated with baseline Mf counts (Spearman’s rho: 0.66, P = 0.001),
and absolute CFA levels were significantly higher at baseline in the individuals who later
developed moderate AEs. CFA levels were significantly higher in the moderate AE group
compared to the no/mild AE groups at all time-points (Figure 2.3). CFA levels increased
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in all groups after treatment, but the difference was only significant at the 48hr time-point
(P = 0.048 by Wilcoxon signed-rank test) compared to the baseline level in the moderate
AE group. There was no difference in absolute CFA levels between the two treatment
arms at any time-point.
Baseline Mf counts were higher in individuals who developed moderate AEs
(geometric mean 4491 Mf/mL compared to 1111 Mf/mL in the mild AE group and 1351
Mf/mL in the no AEs group), and this difference was significant (P = 0.017 by the
Kruskal-Wallis test).

Filarial DNA levels.
Thirty-three percent of participants had detectable filarial DNA in plasma
collected before treatment. There was no correlation between pre-treatment Ct values and
baseline Mf counts (Spearman’s rho: -0.1). Filarial DNA was detected in plasma of all
subjects at 8 hours post-treatment. Also, filarial DNA levels increased (Ct values
decreased) after treatment in persons with filarial DNA detected at baseline. DNA levels
quickly increased for the first 12-24 hours after treatment, after which they start to
decrease. However, filarial DNA was still detectable in plasma in 95% of individuals
72hr post-treatment. There was a statistically significant difference in delta Ct values
between the three AE groups at 12 and 24 hours post-treatment, and this difference was
due to significantly higher delta Ct values (larger increase in DNA levels) in the moderate
AE group compared to the mild AE group (Figure 2.4). A similar trend was observed
between the moderate and no AE groups, but the difference was not statistically
significant due to the small number of individuals in the no AE group (N=5). There were
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no significant differences in filarial DNA levels in plasma by treatment arm at any timepoint.

CIC levels.
CIC were detected in all samples, and the range at baseline was 108-1312 ng
AHG equivalent/mL (median 417 ng). Baseline CIC levels were positively correlated
with Mf counts (Spearman’s rho: 0.68, P = 0.006). There was no difference in absolute
CIC levels between the AE groups at any time-point (Supplemental Table 2.1). CIC
levels were relatively stable after treatment, and there were no consistent patterns as
differences included both increases and decreases.

2.5

Discussion.
The aim of this study was to determine the role of host cytokines, and filarial
components released by parasites after treatment, in the development of AEs in LFinfected individuals. This is the most detailed study to date of cytokine responses that
occur in persons with AEs after treatment of LF. We identified 22 cytokines that were
differentially regulated post-treatment between the three AE groups. The majority of
these cytokines increased more post-treatment in persons who developed moderate AEs.
Our data are consistent with previously published results such as increases in IL-6, TNFα and IL-10 post-treatment in people with AEs (14, 15). However, we also found that
many other cytokines increased in participants with moderate AEs.
Plasma levels of filarial DNA and CFA both increased after treatment, and posttreatment increases in CFA were much more dramatic in people who developed moderate
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AEs than in those with no/mild AEs. Treatment with ALB/DEC and IVM/DEC/ALB
resulted in similar changes in CFA and filarial DNA levels after treatment, suggesting
that the two treatments have similar activity against Mf and adult filarial worms in the
first days after treatment. CFA levels increased slightly later after treatment than filarial
DNA, but the CFA increases persisted for a longer time. This result is consistent with
prior reports of increased CFA levels 5-7 days post-treatment (24, 25). Taken together,
our results suggest that cytokines, filarial DNA, and CFA all may be involved in the
pathogenesis of AEs. It is likely that the cytokine responses are triggered by molecules
that are released from dying parasites. However, it is unclear whether cytokine release is
triggered by phagocytosis of parasite debris or by direct interaction of parasite molecules
with ligands on the surface of host cells. Compared to filarial DNA and CFA levels, CIC
levels were stable after treatment, and there was no difference in CIC levels between the
AE groups at any time-point. These results suggest that CIC may not be involved in the
pathogenesis of moderate AEs.
Cytokine changes have been extensively studied in patients with septicemia or
after exposure to endotoxin with sequential increases in TNF-α, IL-1β, IL-6, IL-1Ra and
IL-10 (26). The cytokine pattern in this study was somewhat similar in that TNF-α was
the first to increase with a peak at 8hr post-treatment. IL-6 had the largest increase (a 13fold increase in the moderate AE group) with a peak at 12hr. IL-10, which increases later
after endotoxin exposure was not delayed in this study; it rose by 8hr and peaked at 12hr.
Increases in pro-inflammatory cytokines may be stimulated by release of Wolbachia from
dying filarial worms, but additional studies will have to be conducted to test this
hypothesis. Dramatic increases in MCP-1 (monocyte chemoattractant protein 1) and
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MIP-1β/1α (macrophage inflammatory protein 1β/1α) in persons with moderate AEs
suggest that monocytes and/or macrophages are involved in the pathogenesis of AEs.
Both of these cytokines are released by macrophages after endotoxin exposure (27), so
this finding is consistent with the Wolbachia release hypothesis. Although Wolbachia do
not contain lipopolysaccharide, they do contain endotoxin-like lipoproteins that interact
with cellular ligands TLR2 and TLR6 (9, 11, 13).
Several baseline characteristics are known to be correlated with development of
AEs after treatment of LF. For example, high Mf counts are a known risk factor (7), and
our study confirmed that this is the case. High CFA levels have not been previously
identified as a risk factor for AEs. Perhaps because antigen levels were not measured.
However, the association is not surprising, because CFA levels are positively correlated
with Mf counts. The finding that participants with elevated levels of certain cytokines
prior to treatment were at increased risk for moderate AEs was not anticipated. This was
especially true for eotaxin-1, a chemokine secreted by various cells that attracts
circulating eosinophils to their respective tissue (28). One potential explanation for this
finding is that individuals with high levels of eotaxin-1 may have activated eosinophils
that are poised for attack. These cells rapidly kill parasites that have been damaged by
anthelmintic drugs and this may trigger a more vigorous pro-inflammatory response that
results in AEs. This hypothesis is supported by the finding that eotaxin-1 deficient mice
have reduced eosinophil responses to TLR2 activation and filarial antigen exposure, and
the finding that macrophages from these mice produce less IL-6 (29). Additional research
will be needed to understand the apparent link between eotaxin-1 and AEs.
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Samples from the PNG trial were ideal for our study because of the high rate of
AEs, the detailed clinical information available for participants, and the availability of
plasma at many time-points after treatment. One limitation is that we were unable to
assess Wolbachia in the plasma samples for technical reasons. Another limitation is that
the correlations we observed do not prove causation.
In conclusion, this study has provided additional information on changes in
plasma cytokine levels and in filarial worm components that are associated with moderate
AEs after LF treatment. We have also shown that high Mf counts and high levels of CFA
and eotaxin-1 at baseline are associated with increased risk for moderate AEs. Taken
together, our results suggest that components released from filarial worms interact with
the host immune system to release pro-inflammatory cytokines that lead to moderate AEs
with fever and associated symptoms. More work is needed to identify the specific filarial
worm components that are responsible for this immune activation, but Wolbachia
endobacteria represent an attractive candidate. However, they are unlikely to be the only
contributor, because similar AEs occur in patients after treatment of loiasis, and Loa loa
does not contain Wolbachia (30). Improved understanding of the pathogenesis of AEs
may lead to strategies to prevent or manage AEs in ways that increase compliance with
MDA, which is essential for the success of LF elimination programs.
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Figure 2.1: Cytokine levels pre- and post-treatment in individuals with no, mild and moderate
adverse events (AEs).
Mean cytokine levels (± SE) in the three AE groups over time. IL-6 [A], IL-10 [B], MCP-1 [C]
and MIP-1β [D] increased post-treatment in the moderate AE group while there were no
significant changes in the no or mild AE groups. Significance (Kruskal-Wallis H Test): *
represents P < 0.05, ** represents P < 0.01.
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Figure 2.2: Eotaxin-1 levels pre- and post-treatment in individuals with no, mild and moderate
adverse events (AEs).
Mean eotaxin-1 levels (± SE) for all three adverse event (AE) groups over time. Eotaxin-1 levels
were significantly higher at all time-points in the moderate AE group compared to the no and/or
mild AE groups. Significance (Kruskal-Wallis H Test): * represents P < 0.05, ** represents P <
0.01.
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Figure 2.3: Circulating filarial antigen (CFA) levels pre- and post-treatment in individuals with
no, mild and moderate adverse events (AEs).
Mean Wb (W. bancrofti) CFA levels (± SE) for each AE group over time. CFA levels were
significantly higher in the moderate AE group than in the no and mild AE groups. Significance
(Kruskal-Wallis H Test): * represents P < 0.05, ++ represents P < 0.01. CFA levels were
significantly higher at 48 hours post-treatment compared to baseline in the moderate AE group
(P-value= 0.048 by Wilcoxon signed-rank test).
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Figure 2.4: Filarial DNA levels pre- and post-treatment in individuals with no, mild and
moderate adverse events (AEs).
Filarial DNA levels in plasma (expressed as delta Ct ± SE) after treatment by adverse event (AE)
group. Ct values decreased after treatment in all three AE groups, signifying an increase in
filarial DNA levels in plasma. Mean delta Ct values were significantly greater in the moderate
AE group when compared to the mild AE group at 12 (P = 0.025) and 24 (P = 0.020) hours posttreatment (by ANOVA).
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Table 2.1: Changes in cytokines at different times after treatment in persons who developed
moderate adverse events (AEs) after treatment of filariasis compared to those with no or mild
AEs.
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Hours post-treatment.

These differences were due to significant increases (represented with plus signs) in cytokine
levels in the moderate AE group compared to the no and/or mild AE groups (Kruskal-Wallis
analysis followed by post-hoc tests to determine which AE groups were statistically different).
IL-2, IL-15 and RANTES were exceptions as these cytokines were decreased (represented with
minus signs) before and/or after treatment in the moderate AE group. Significance (by the
Kruskal-Wallis H Test): + or - corresponds to P < 0.05; ++ or - - corresponds to P < 0.01.
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Supplemental Table 2.1: Levels of circulating immune complexes (CIC) in plasma at different
times after treatment in the three adverse events (AEs) groups.
Hours PostTreatment
Moderate AEs
(N=7)
Mild AEs
(N=10)
No AEs
(N=5)

0

8

12

24

36

48

72

514
(144)
373
(96)
611
(175)

512
(168)
384 (96)

539
(146)
378 (90)

510
(158)
391 (90)

514 (95)

534 (162)

615
(129)

635
(154)

699
(139)

587
(207)
361
(207)
698
(154)

386
(102)
702
(143)

396 (110)
648 (151)

Mean CIC plasma concentration, ng aggregated human immunoglobulin equivalent/mL (+ SE).
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Chapter 3
Systems analysis-based assessment of post-treatment
adverse events in lymphatic filariasis
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3.1

Summary.
Background: Lymphatic filariasis (LF) is a neglected tropical disease, and the
Global Program to Eliminate LF delivers mass drug administration (MDA) to 500 million
people every year. Adverse events (AEs) are common after LF treatment.
Methodology/Principal Findings: To better understand the pathogenesis of AEs,
we studied LF-patients from a treatment trial. Plasma levels of many filarial antigens
increased post-treatment in individuals with AEs, and this is consistent with parasite
death. Circulating immune complexes were not elevated in these participants, and the
classical complement cascade was not activated. Multiple cytokines increased after
treatment in persons with AEs. A transcriptomic analysis was performed for nine
individuals with moderate systemic AEs and nine matched controls. Differential gene
expression analysis identified a significant transcriptional signature associated with posttreatment AEs; 744 genes were upregulated. The transcriptional signature was enriched
for TLR and NF-κB signaling. Increased expression of seven out of the top eight genes
upregulated in persons with AEs were validated by qRT-PCR, including TLR2.
Conclusions/Significance: This is the first global study of changes in gene
expression associated with AEs after treatment of lymphatic filariasis. Changes in
cytokines were consistent with prior studies and with the RNAseq data. These results
suggest that Wolbachia lipoprotein is involved in AE development, because it activates
TLR2-TLR6 and downstream NF-κB. Additionally, LPS Binding Protein (LBP, which
shuttles lipoproteins to TLR2) increased post-treatment in individuals with AEs.
Improved understanding of the pathogenesis of AEs may lead to improved management,
increased MDA compliance, and accelerated LF elimination.
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3.2

Introduction.
Lymphatic filariasis (LF) is a disabling neglected tropical disease that is caused
by the mosquito-borne filarial parasites Wuchereria bancrofti, Brugia malayi and B.
timori. Adult worms live in the human host’s lymphatic system and release larval
parasites (microfilariae or Mf) that circulate in the blood. Infection and host
inflammatory responses to the parasite can lead to severe morbidity including
lymphedema, hydrocele and elephantiasis (1). To combat this disease the WHO launched
the Global Program to Eliminate Lymphatic Filariasis (GPELF) in the year 2000 with the
goal of eliminating LF as a public health problem by 2020. The program uses mass drug
administration (MDA), to cure infections, prevent disease, and reduce transmission of
new infections. As of 2016 a total of 6.7 billion treatments had been delivered to more
than 850 million individuals (2), making GPELF the largest public health intervention for
an infectious disease to date based on MDA. Drugs used for LF MDA include
albendazole (ALB), ivermectin (IVM) and diethylcarbamazine (DEC). MDA with twodrug combinations is usually provided annually for 4-6 years. The combinations used are
ALB with IVM in sub-Saharan Africa and ALB with DEC in other regions (1). New
studies have shown that combining all three drugs increases the anti-filarial effect and
potentially decreases the number of required treatment rounds (3-7). This new triple
therapy (IDA) was recently recommended by the WHO as the preferred regimen for LF
elimination in some settings (8).
Although LF treatment is safe, transient mild to moderate systemic adverse events
(AEs) are common following treatment, and these are especially common in individuals
with circulating Mf (3). Furthermore, the risk of AEs and AE severity are positively
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correlated with blood Mf counts (Mf/mL) (9). Systemic AEs are not direct effects of the
drugs on the host, because they are quite uncommon in uninfected individuals (10). The
pathogenesis of these AEs is not completely understood, but they are believed to be
trigged by host responses to dying filarial worms. Post-treatment AEs have been
associated with increases in plasma levels of IL-6, TNF-α and soluble TNF receptor (11,
12). We recently reported significant increases in 16 cytokines in persons who
experienced AEs after treatment during a clinical trial that was performed in Papua New
Guinea (13). These results were consistent with LPS-like stimulation of cytokines with
increases in TNF-α, IL-1β, IL-6, IL-1RA and IL-10.
Wolbachia are intracellular α-proteobacteria that are present in filarial species that
cause LF. The bacteria are hypothesized to trigger AEs when they are released by dying
parasites after treatment. One study detected free Wolbachia DNA in blood collected 448 hours after LF treatment in individuals with moderate and severe AEs, but bacterial
DNA was not detected in blood from most individuals with no or mild AEs (14). Some
features of AEs are consistent with the effects of LPS. A filarial (Brugia malayi) antigen
with LPS-like characteristics was described some years ago (15). However, the B.
malayi-associated Wolbachia genome (16) does not include orthologues of genes
responsible for the biosynthesis of lipid A (a component of LPS) (17). It is therefore
unlikely that B. malayi Wolbachia contains LPS in its cell wall. Bioinformatic analysis of
the Wolbachia genome predicts the presence of a Wolbachia lipoprotein: peptidoglycanassociated lipoprotein (PAL) (18). A synthetic, lipolated version of the N-terminus of
Wolbachia PAL can signal through TLR2-TLR6 and induce pro-inflammatory responses
in vitro in murine and human cells and in vivo in mice (18). Additionally, the diacylated
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N-terminal polypeptide of the Wolbachia PAL (WoLP) was identified as the main trigger
for a neutrophil inflammatory response through a TLR2-TLR6 dependent mechanism in
vivo in human samples from individuals infected with Onchocerca volvulus (19).
Recently PAL was confirmed by proteomics as one of the most abundant proteins in
extracts from adult B. malayi female worms(20).
Besides Wolbachia, post-treatment AEs could also be triggered by immune
complexes (IC) that develop after treatment of LF. ICs are aggregated antigens,
antibodies, and components of the complement cascade that can activate proinflammatory pathways (21). It has been reported that filarial antigen levels increase with
a concurrent decrease in filarial specific antibodies post-treatment, and these changes
were temporally associated with the development of AEs, suggesting that AEs might be
caused by IC (22). Circulating IC (CIC) have also been shown to increase post-treatment
(23), and CIC precipitated from LF-infected individuals can activate granulocytes to
release pro-inflammatory cytokines (24). CIC activate the classical complement pathway.
AEs are common after treatment for LF, and fear of AEs reduces population
compliance with MDA (25). Therefore, the goal of this study was to improve
understanding of the pathogenesis of AEs after LF treatment. We hypothesized that AEs
are caused when filarial worm components are released after treatment and interact with
the host innate or adaptive immune systems and that this would be associated with
specific biomarker and gene expression profiles. To test this hypothesis we measured
filarial antigen, CIC, LPS Binding Protein (LBP) and components of the complement
cascade in plasma before and after treatment, and we studied host transcriptional
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responses and cytokine profiles in LF-infected individuals who experienced AEs after
treatment.

3.3

Methods.
Study design and sample collection.
Buffy coat and plasma samples were collected during an open label filiariasis
treatment study in the Agboville District in southeastern Côte d’Ivoire (Clinicaltrials.gov
NCT # 02974049). Written informed consent was obtained from all participants. Adults
with W. bancrofti microfilaremia were randomly assigned to one of four treatment arms
(all oral medications): the standard LF treatment regimen for Côte d’Ivoire (200µg/kg
IVM plus 400mg ALB), IDA: 200µg/kg IVM plus 6mg/kg DEC and 400mg ALB, a
single 400 mg dose of ALB, or a single 800 mg dose of ALB. A subset of ninety-five
individuals treated with either IVM/ALB, IDA or 400mg ALB had samples processed for
use in the AE study described in this paper. We selected these individuals based on the
availability of pre- and post-treatment samples and clinical AE data. Metadata of these 95
individuals is shown in Supplemental Table 1.
A physical examination was performed shortly before treatment, and vital signs
were recorded. A review of systems (ROS) questionnaire was also completed to assess
subjective symptoms prior to treatment. Venous blood (3 to 4 mL in EDTA) was
collected immediately before participants received treatment. Participants were
interviewed and examined the next day to assess AEs, and venous blood was collected
approximately 24 hours after treatment. Blood samples were centrifuged within an hour
of collection, and plasma was removed. The buffy coat (approximately 500µL) was
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carefully aspirated with a pipette and added to 1.8mL of RNAlater (Ambion, Foster City,
CA). The plasma samples and buffy coat/RNAlater samples were stored at the study site
at -20°C, shipped frozen, and later stored at -80°C.

Adverse event classification.
AEs were categorized as mild, or moderate. Those with moderate AEs (n=9) had
at least two new or worsening subjective symptoms plus one objectively measured
change in their vital signs (an increase in axillary temperature of ≥ 0.8°C to at least
37.4°C post-treatment and/or a decrease in sitting systolic blood pressure of at least 20
mm Hg). Individuals with subjective or objective AEs that did not fulfill the criteria for
moderate AEs were considered to have had mild AEs (n=24). Individuals with no new
objective or subjective symptoms after treatment were considered to have no AEs (n=62).

Circulating filarial antigen assay.
A direct sandwich enzyme immunoassay (EIA) was performed as previously
described (13). This assay uses the monoclonal antibody AD12 that binds to a
carbohydrate epitope on circulating filarial antigen (CFA). It is important to note that the
carbohydrate epitope recognized by AD12 is present in many filarial glycoproteins (26).
However, the high molecular weight CFA is the only filarial antigen that is frequently
detected in the blood of W. bancrofti-infected individuals. Pre- and post-treatment plasma
samples from 95 individuals were tested in duplicate. The detection range of the CFA
EIA was 6.3 to 400 ng/mL. CFA was detected in all samples, but two individuals had
extremely high CFA levels that were above the upper detection limit of the assay. These
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samples were retested after dilution to obtain baseline CFA concentrations. The percent
change in CFA relative to baseline following treatment was calculated for each
participant. Sample pairs with pre-treatment values less than 20 ng/mL (7 individuals)
were excluded from the percent calculations, because they were near the lower detection
limit of the assay. Kruskal-Wallis H tests were used to compare percent change values
and absolute values between the three AE groups and the three treatment arms. Wilcoxon
signed-rank tests were used to compare pre- and post-treatment CFA levels within the
three AE groups.

Immunoprecipitation and Western blot.
Nine paired (pre- and post-treatment) samples with high CFA levels at baseline
were selected for this analysis; six of these participants had moderate AEs, one had mild
AEs, and two had no AEs. 15mg of a monoclonal antibody (DH6.5) that detects the same
carbohydrate epitope as AD12 was directly conjugated to 2mL of agarose Affigel 10
beads (Bio-Rad, Hercules, CA) according to the manufacturer’s protocol. Conjugated
beads were stored as a 50% solution in PBS. 40µL of conjugated beads were mixed with
50µl of human plasma and 300µl PBS and rocked overnight at 4¹C. The beads were
washed four times with cold PBS and then boiled in 1X NuPAGE LDS sample buffer
(Invitrogen, Carlsbad, CA) to release bound antigens. Proteins were resolved by SDSPAGE using a 4-12% bis-tris NuPAGE gradient gel (Invitrogen) and transferred to
0.45µM nitrocellulose membrane (Amersham, Piscataway, NJ). Membranes were
blocked with 5% milk in phosphate buffered saline with tween-20 (PBS-T) followed by
incubation with a peroxidase-conjugated AD12 antibody (1:3000 dilution) for one hour at
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room temperature. After washing, membranes were incubated with Clarity Western ECL
substrate (Bio-Rad). Chemiluminescence was detected by a ChemiDoc imager (Bio-Rad),
and results were analyzed using Image Lab 5.2.1 software.

Immune complex assay.
CIC were measured with a C1q ELISA. C1q was purchased (Sigma-Aldrich, St.
Louis, MO), and a previously published protocol was followed (13). Plasma samples
were available from 41 individuals for this assay (8 with moderate AEs, and 33 with no
AEs), and both pre- and post-treatment samples were tested in duplicate. Negative control
samples (plasma samples from healthy North American subjects and deionized water)
were tested on each plate. Values were expressed as µg/mL of AHG (aggregated human
gamma globulin) (Invitrogen). The range of detection for the CIC ELISA was 0.0006 to 6
µg/mL of AHG, and all samples had detectable CIC. Mann-Whitney U tests were used to
compare absolute CIC levels between the two AE groups pre- and post-treatment. The
Wilcoxon signed-rank test was used to compare post-treatment CIC levels to baseline
levels within AE groups. The Kruskal-Wallis H test was used to compare absolute CIC
levels between the three treatment arms post-treatment.

Complement component assays.
Nine individuals with moderate AEs were matched to individuals with no AEs
following treatment. Matching was based on age, sex, baseline Mf count, and treatment
arm (Supplemental Table 2). Complement component 3 (C3), complement component 4
(C4) and Factor B (FB) were measured in the 36 samples (18 matched case-control
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subjects pre- and post-treatment) with ELISA kits (AssayPro, St. Charles, MO). The C3
and C4 assays were competitive enzyme immunoassays, and the FB assay was a
sandwich ELISA. Each sample was tested in duplicate and manufacturer’s protocol was
followed. Paired t-tests were used to compare pre- and post-treatment complement
component levels by AE group.

LPS binding protein assay.
LBP was measured with a sandwich ELISA kit (Abnova, Taipei, Taiwan). Plasma
samples from the same 18 matched case-control subjects were included. Each sample was
tested in duplicate and manufacturer’s protocol was followed. Paired t-tests were used to
compare pre- and post-treatment levels within both AE groups. The range of detection for
the LBP ELISA was 5 to 50 ng/mL.

Cytokine assays.
Twenty-seven cytokines (IL-1β, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9,
IL-10, IL-12 (p70), IL-13, IL-15, IL-17, basic FGF, eotaxin-1, G-CSF, GM-CSF, IFN-γ,
IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-BB, RANTES, TNF-α, and VEGF) were
measured with the MAGPIX system with the Bio-Plex Human 27-Plex Cytokine Panel
and Bio-Plex Cytokine Reagent Kit (Bio-Rad). Plasma samples from the same 18
matched-control subjects were included. A previous paper includes the detailed protocol
(13). Briefly, all samples were tested in duplicate, standard curves were calculated using
the manufacturer’s software, and the analysis considered mean concentrations (pg/mL)
from two duplicate wells. Wilcoxon signed-rank tests were used to determine whether
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cytokine levels changed after treatment in either of the two AE groups. Mann-Whitney U
tests were used to determine whether pre- or post-treatment cytokine levels were different
between the two AE groups. For graphing, fold changes were calculated for each
cytokine by AE groups, and samples with cytokines below the detection limit were
assigned a value equal to half the value of the lowest pre-treatment sample concentration
measured for that cytokine.

RNA preparation.
RNA was extracted from pre- and post-treatment buffy coat samples from the
same 18 matched case-control subjects. Total RNA was extracted using Qiagen RNeasy
kits (Qiagen, Hilden, Germany) according to the manufacturer’s protocol with an added
homogenization step and on-column DNase digestion as follows. For each sample 200µL
of the buffy coat/RNAlater mixture was added to 700µL of the kit’s RLT buffer and
vortexed. The mixture was then added to a QIAShredder column (Qiagen) and
centrifuged for 2 min at 16,000g. The flow-through was added to 700µL of 70% ethanol,
and this mixture was added to a RNeasy column. Bound RNA was eluted in 30µL
RNase-free water and stored at -80°C. The quality and quantity of RNA was verified with
a Bioanalyzer 2100 (Agilent Technologies, Cedar Creek, Texas). Samples were
processed with the TruSeq Stranded Total RNA LT Sample Prep Kit with Ribo-Depletion
using the manufacturer’s protocol (Illumina, San Diego, CA). The RNA was high quality
(average RIN value 9.3, range 8.5-10).
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RNA sequencing and mapping.
The 36 samples were sequenced in two batches. The first 14 samples were
sequenced with the HiSeq2000 (2x 100 PE run and Illumina TruSeq Stranded Total
RNA) platform, and the remaining 22 samples were sequenced with HiSeq4000 (2x 150
PE run and Illumina TruSeq Stranded Total RNA). Between 28-41 million read
fragments per sample were mapped to 19,864 protein-coding genes. Raw reads were
mapped to protein coding genes using HISAT2 (version 2.0.5) (27), and the human
reference genome GRCh38.84. FeatureCounts (28) was used to count reads per gene.

Differential gene expression and overall expression patters.
DESeq2 (29) was used to generate normalized read counts and to identify
differentially expressed genes between the different comparator groups (namely AEs vs.
no AEs and pre- vs. post-treatment). The program “R” with the biocLite package
“DESeq2” was used. Gene expression results from individuals before and after treatment
were considered to be repeated measures for the analysis. Principal component analysis
(PCA) was performed for 500 genes with the greatest variability in expression (based on
DESeq2 output, default settings), and distance metrics statistics (30) were used to
determine whether groupings affected overall expression patterns. A clustering
dendrogram (Euclidean distance, complete linkage) was also used to illustrate overall
expression patterns, and this method considered all genes. A two-tailed binomial
distribution with unequal variance (for categorical data), and Mann-Whitney U tests (for
continuous variables) were used to identify over-represented metadata variables in the
different clustering groups such as baseline Mf/mL and treatment group.
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Functional enrichment in the post-treatment AE group.
The online tool WebGestalt (31) was used to identify enriched KEGG pathways
within genes that were upregulated post-treatment during AEs. The reference set was a
list of all 19,864 genes with expression signals in the RNAseq data, and the default
values were used except the significance level (FDR < 0.05). The program i-cisTarget
(32) was used to identify enriched transcription factor binding sites in the upregulated
gene set using default settings and database version 4.0.

Identification of similar expression profiles.
GeneQuery is an online tool that can search the PubMed GEO database and
compare transcriptional signatures to published gene expression profiles (33). The input
for the post-treatment AE profile were 744 genes that were identified by differential gene
expression (DESeq2) to be upregulated post-treatment in individuals with moderate AEs.

Changes in peripheral blood leukocyte populations after treatment
CIBERSORT(34) is an analytical tool that can estimate the abundances of 22
leucocyte subtypes based on RNA-seq data. Pre- and post-treatment DESeq2 normalized
read counts were used as input for the program. The standard LM22 (22 immune cell
types) was the signature gene file, and all default settings were used. Thirteen cell
subtypes had very low representation in this dataset (totaling less than 4% in all 36
samples), so the analysis was limited to the remaining subtypes. Percent change for each
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cell type post-treatment was calculated for the two AE groups, and Mann-Whitney U
tests were used to assess the significance of differences by AE group.

Prioritization of the genes with altered regulation post-treatment in individuals with
AEs.
Random forest (RF) analysis was used to prioritize the 678 genes that were
differentially expressed in individuals with moderate post-treatment AEs.

RF was

performed using the “R” package “randomForest” with 1000 trees and default values to
analyse DESeq2 normalized read counts. Differentially expressed genes were ranked
based on decreasing Mean Decrease in Accuracy values for 10 separate RF models. The
Mean Decrease in Accuracy is the decrease in model accuracy from permuting the values
in each feature. This metric is used to compare the impact of the variables in the model,
and a large positive value indicates that a variable was closely linked to AE group across
the dataset.

Preparation of cDNA for validation of selected differentially expressed genes.
Additional RNA was extracted from residual buffy coat samples that were
available for 34 of the 36 samples that were subjected to expression profiling (17
individuals pre- and post-treatment) as described above. Extracted RNA was treated with
DNase I (Invitrogen), and RNA was measured with a NanoDrop 1000 Spectrophotometer
(Thermo Scientific, Waltham, MA). Each sample was diluted to approximately 0.5ng/µL
RNA with RNase-free water. cDNA was prepared with SuperScript II Reverse
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Transcriptase (Invitrogen) and with Oligo(dT)12-18 according to the manufacturer’s
protocol.

Validation of the top differentially expressed genes by quantitative reversetranscription PCR (qRT-PCR).
SYBR Green based assays were performed for the top eight genes based on the
RF analysis (DIP2B, ZCCHC6, RBPJ, PELI1, FNDC3B, TLR2, LTBR, NT5C2) that were
upregulated in peripheral blood leukocytes (PBL) after treatment in participants who
experienced moderate AEs . Four housekeeping genes (SDHA, ACTB, HPRT1 and
YWHAZ) were used as controls for these experiments. We chose these based on prior
validation as housekeeping genes by others (35) and because our results confirmed their
stable gene expression before and after treatment. Pre-validated primer sets for the eight
target genes were purchased from KiCqStart SYBR Green Primers (Sigma-Aldrich), and
primers for the four housekeeping genes were made using previously published
sequences (IDT, Coralville, IA) (Supplemental Table 3). Real-time PCR reactions were
performed with 10µL of SYBR Green Master Mix (Applied Biosystems, Foster City,
CA), 450 nmol/L of each primer, and 2µL cDNA (approx. 1ng RNA) with a final volume
of 20µL. Thermal cycling was performed for 40 cycles with a QuantStudio 7-Plex RealTime PCR System (Applied Biosystems), and cycle threshold (Ct) values were
determined using the manufacturer’s software. All samples were tested in duplicate, and
each plate included a negative water control and a RNA sample that had not been treated
with reverse transcriptase. Delta delta Ct values were calculated (36), using the geometric
mean Ct value of three housekeeping genes (SDHA, ACTB and YWHAZ) as a
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normalization factor (35). Student’s t-tests were performed to compare baseline and posttreatment delta Ct values by AE group.

Statistical methods.
All statistical analyses were performed with IBM SPSS (version 23). ShapiroWilk tests were used to test for normality in each sample set, and additional tests were
performed as described in each section above. Logistic regression analysis was performed
with the binary dependent variable AEs (moderate AEs vs. no AEs). The independent
variables considered included age, sex, treatment arm, baseline Mf/mL, and baseline
CFA level.
Separate RF analyses of gene expression and plasma biomarker data were
performed 10 times using 1000 trees. The output was the average Mean Decrease in
Accuracy over the 10 runs for each variable.

Ethical review.
Institutional review boards in Cleveland, USA (University Hospitals Cleveland
Medical Center IRB #08-14-13) and in Côte d’Ivoire (Comité National d’Ethique et de la
Recherche, CNER, N: 008/MSLS/CNER/-kp) approved the clinical trial study protocol.
Written informed consent was received from all participants prior to inclusion in the
study.
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3.4

Results.
Study population.
This study of the pathogenesis of AEs that occur after LF treatment used human
samples that were obtained as part of a clinical trial for LF that was conducted in Côte
d’Ivoire. Full results from that study have not yet been published, but early results from
the study have been reported in published abstracts (4, 5). Briefly, 189 W. bancroftiinfected adults were randomly assigned to one of four treatment arms as described above,
and all participants had AE assessments performed 24 hr after treatment. The AE study
enrolled a subset of 95 treated participants. Supplemental Table 1 summarizes the
specific analyses that were performed on samples from each of the 95 individuals. Nine
of these participants experienced moderate AEs (Table 1), 24 had mild AEs, and 62 had
no AEs. There was no difference in age or sex distribution between the three AE groups
(Supplemental Table 4).

Multiple additional filarial antigens were detected in post-treatment plasma
samples.
Baseline CFA levels were positively correlated with baseline Mf counts
(Spearman’s rho: 0.51, P < 0.001), and absolute CFA levels were significantly higher at
baseline in individuals who developed moderate AEs compared to individuals who
developed mild or no AEs after treatment (P = 0.012 by Kruskal-Wallis H test). Plasma
CFA levels increased post-treatment in all three AE groups, but the increases were
greater in persons with moderate AEs (P < 0.05 by Kruskal-Wallis H test) (Figure 1A).
Percent changes in CFA levels post-treatment were significantly lower in the individuals
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treated with only ALB compared to those in individuals treated with IVM/ALB or IDA
(P < 0.0001 by Kruskal-Wallis H test).
Western blot analysis was performed for nine pre- and post-treatment plasma
pairs to compare CFA patterns detected in plasma before and after treatment. All nine
pretreatment plasma samples contained only a single high molecular weight parasite
antigen as expected, and this antigen was also present in post-treatment plasma samples.
However, four of the post-treatment plasma samples contained many parasite antigens
that were not present before treatment. Two examples are shown in Figure 1B (P1 had
moderate AEs, and P2 had mild AEs), and this pattern was also observed in plasma from
two other participants who experienced moderate AEs following treatment. Western blot
results obtained with five other post-treatment plasma samples tested (3 from persons
with moderate AEs, and 2 from persons with no AEs) were no different from those
observed in pre-treatment samples.

CIC did not increase post-treatment and the classical complement pathway was not
activated in individuals with moderate AEs.
All pre- and post-treatment samples contained CIC. However, there was no
difference in CIC levels between the two AE groups before or after treatment, and CIC
levels did not significantly change after treatment in either AE group (Supplemental
Figure 1). There was also no difference in post-treatment CIC levels between the
treatment arms.
C3 levels significantly decreased post-treatment in individual with moderate AEs,
but this change was not observed in individuals with no AEs (Figure 2A). C4 levels did
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not change in either AE group (Figure 2B). Factor B levels decreased post-treatment in
most individuals with moderate AEs, but three individuals had increases in FB levels, and
the group differences were not significant (Figure 2C).

LPS binding protein levels increased post-treatment in individuals with moderate
AEs.
LBP was detected in all pre- and post-treatment samples. LBP levels increased
post-treatment in individuals with moderate AEs (P = 0.0007 by paired t-test), but they
did not increase in individuals with no AEs (Figure 2D).

Many plasma cytokines increased in plasma after treatment in persons who
experienced moderate AEs.
Plasma cytokine levels before and after treatment are shown by AE group in
Figure 3. Seven cytokines (IL-8, MCP-1, VEGF, TNF-α, MIP-1β, G-CSF and IFN-γ)
increased post-treatment only in individuals who experienced moderate AEs (P < 0.05 by
Wilcoxon signed-rank test). Five cytokines (IL-6, IL-10, IL-1RA, IP-10 and MIP-1α)
increased post-treatment in individuals with and without AEs (P < 0.05 by Wilcoxon
signed-rank test), but three of these (IL-6, IL-10 and IL-1RA) had significantly higher
levels post-treatment in individuals with moderate AEs compared to individuals with no
AEs (P < 0.05 by Mann-Whitney U tests) (Figure 3). The remaining 15 cytokines (IL-1β,
IL-2, IL-4, IL-5, IL-7, IL-9, IL-12 (p70), IL-13, IL-15, IL-17, basic FGF, eotaxin-1, GMCSF, PDGF-BB and RANTES) did not change after treatment in either AE group. There
was no difference in pre-treatment cytokine levels between individuals that would
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develop moderate AEs and individuals that would not develop AEs for any of the 27
cytokines.

Changes in gene expression associated with moderate post-treatment AEs.
Raw and processed RNA-seq data are available to the public on NCBI’s Gene
Expression Omnibus (Accession number: GSE110146).
We analyzed changes in gene expression in PBL after treatment to further
elucidate host responses associated with AEs. Post-treatment gene expression profiles
from persons who developed moderate AEs clustered together using a clustering
dendrogram based on gene expression profiles across all genes (Figure 4A). Posttreatment AE samples were significantly overrepresented in the fourth group (bolded in
Figure 4A, P-value < 0.0001 for enrichment within the cluster, two-tailed binomial
distribution with unequal variance). Higher levels of baseline Mf/mL were also observed
in this group (P-value = 0.038, Mann-Whitney U test), but none of the other metadata
categories (treatment arm or village) were over-represented. Age also did not affect
clustering. A similar pattern was observed by principal components analysis (Figure 4B),
where post-treatment moderate AE samples clustered together and were clearly separated
from their pre-treatment controls (P-value = 0.005 by PERMANOVA (30)). No other
differences were significant between the four groups by PCA.
We used differential gene expression analysis to identify the genes that were
responsible for the clustering of the post-treatment moderate AE samples. At a very
stringent significance threshold (P < 10-5 according to DESeq2 output), 783 genes were
identified to be upregulated after treatment (n=744) or before treatment (n=39) in

87

individuals who experienced moderate AEs (Figure 4C). No differences were observed
pre- or post-treatment in individuals with no AEs when this stringent significance
threshold was used. However, at a less stringent P-value of 0.05, there were 126 genes
upregulated post-treatment and 19 genes upregulated pre-treatment in individuals without
AEs (Figure 4D). There was only one overlapping gene in the genes upregulated pretreatment in individuals with and without AEs, whereas the majority of the genes
upregulated post-treatment in individuals with no AEs were also upregulated posttreatment in individuals with AEs (Figure 4E).
We then assessed whether there was evidence for functional enrichment in the
genes upregulated post-treatment in individuals with AEs. Among the 744 upregulated
genes post-treatment in the AE samples a total of 35 enriched biological pathways
(KEGG) were identified (Supplemental Table 5), and these included TLR signaling and
downstream pathways such as NF-κB, TNF and Jak/STAT. Many individual genes in the
TLR signaling pathway, including TLR2, TLR6, STAT1 and STAT2, were identified by
DESeq2 to be significantly upregulated post-treatment in individuals with AEs. A
separate analysis (i-cisTarget) predicted that six transcription factors were overrepresented in the differentially expressed genes (Supplemental Table 6), and three of
these, STAT1, STAT2 and IRF1, are downstream of TLR signaling. Convincingly, STAT1
and STAT2 were therefore identified by two independent analyses, signifying the
importance of these two transcription factors in the development of AEs. IRF1 is
activated by IFN-γ and is a major transcription factor of IL-8, and correspondingly both
IFN-γ and IL-8 levels significantly increased post-treatment in individuals with AEs. The
complete TLR signaling pathway highlighting the individual upregulated genes, KEGG
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pathways and transcription factors, was constructed with the use of the online database
SPIKE (37) (Supplemental Figure 2). Finally we wanted to compare our newly identified
LF AE transcriptional signature to published gene expression profiles. The post-treatment
AE transcriptional signature of the 744 upregulated genes was very similar to multiple
published endotoxin exposure gene expression profiles, in addition to many other profiles
(Supplemental Table 7).
After successfully identifying a significant transcriptional signature of posttreatment AEs, we explored whether a pre-treatment transcriptional signature could
predict what individuals would go on to develop AEs after treatment. There were no
significant differentially expressed genes at baseline between individuals that would
develop moderate AEs, and individuals that would not develop AEs (by DESeq2).

Neutrophils increased and lymphocytes decreased post-treatment.
Changing cell populations can have a large effect on gene expression profiles.
Differential cell counts were unavailable, so cell type proportions were estimated using
the RNA-seq data. This analysis suggested that neutrophils increased more and
lymphocytes decreased more post-treatment in individuals with AEs compared to
individuals with no AEs (Fig. 5A). These changes are consistent with stress-type immune
responses. For simplicity, B cells (memory and naïve), T cells (CD8, CD4 naïve and
memory resting) and NK cells were combined into one category (lymphocytes) in Figure
5A, and ungrouped data are presented in Supplemental Figure 3. Estimated leucocyte
proportions at baseline were very similar between the two AE groups, but individuals
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who experienced post-treatment AEs had significantly fewer estimated memory B cells
compared to individuals who did not develop AEs after treatment (Figure 5B).

Prioritization of genes upregulated post-treatment in individuals with AEs show
that TLR2 is one of the most important genes for the development of AEs.
The genes upregulated post-treatment in individuals with AEs were prioritized by
importance for AE development using a machine-learning tool (RF analysis). This was
done in order to identify genes with the strongest associations between expression levels
and development of AEs and to identify genes of interest for PCR validation. Table 2
shows the top 15 genes that were upregulated in persons who developed moderate AEs
after treatment. However, based on this analysis it was not possible to determine whether
the gene expression changes were the cause or effect of the AEs that were experienced.

Orthogonal validation of expression levels for candidate genes confirmed RNA-seq
data.
qRT-PCR studies were performed to confirm whether expression of genes
identified by DESeq2 and RF analyses was actually increased post-treatment in
individuals with moderate AEs. Increased expression after treatment was confirmed for
seven of the top eight genes (DIP2B, ZCCHC6, PELI1, FNDC3B, TLR2, LTBR and
NT5C2) (Figure 6). Expression of the eighth gene (RBPJ) did not change after treatment
in either AE group. Expression of the housekeeping gene HPRT1, did not change with
treatment in either AE group (as expected).

90

Modeling identified high baseline CFA levels as predictor for development of posttreatment AEs and post-treatment increases in LBP levels as another risk factor.
We were unable to identify any pre-treatment transcriptional signature that could
predict moderate AEs. We therefore wanted to assess if any metadata or baseline
infection parameter was associated with the development of moderate AEs. A logistical
regression was performed to consider effects of age, sex, treatment arm, baseline Mf/mL
and baseline CFA on the risk for development of post-treatment moderate AEs. A total of
71 individuals were included in the model (9 moderate AEs and 62 no AEs). The logistic
regression model was statistically significant, X2 (6) = 22.1, P = 0.0012. The model
explained 50.2% (Nagelkerke R2) of the variance in AE outcome, and correctly predicted
93% of outcomes. However the model was better at predicting people who did not
develop AEs; it correctly predicted

only 44.4% of the individuals who developed

moderate AEs. Increasing baseline CFA levels were associated with increased likelihood
of developing AEs (P = 0.022), but the other independent variables did not significantly
contribute to the model. RF analysis was performed on the same dataset (71 individuals),
and this also identified the baseline CFA level as the best predictor for subsequent
development of AEs. However, treatment arm was also a positive predictor in the RF
model, and could therefore be related with the development of AEs (Table 3). It was
surprising that baseline Mf count was not identified by the logistic regression model or
RF to significantly contribute to correctly predicting AEs. However, baseline Mf counts
were higher in individuals who developed moderate AEs (geometric mean 343 Mf/mL)
compared to individuals with no AEs (geometric mean 188 Mf/mL), and this difference
was significant (P = 0.036 by Mann-Whitney U test). RF analysis was also used to
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identify the variable (CFA, CIC, C3, C4, FB or LBP) that was best at classifying AE
outcome based on post-treatment fold change in the 18 matched case-control subjects.
LBP changes after treatment was the only variable that was significantly associated with
the development of AEs (Supplemental Table 8).

3.5

Discussion.
This study looked at changes in proteins in plasma and changes in gene
expression in PBL in persons who experienced moderate AEs following treatment of LF.

Changes in proteins in plasma in persons who experienced AEs after treatment.
Filarial antigen levels increased in plasma after treatment in individuals with
moderate AEs, and this agreed with our recently published results from a separate clinical
trial (13). Western blot results from this study showed that many new filarial antigens
with the carbohydrate epitope detected by the monoclonal antibody AD12 appeared in the
blood 24 hours after treatment in some individuals. In contrast, only a single high
molecular weight antigen circulates in the blood of W. bancrofti-infected individuals
without treatment (26). We postulate that treatment kills or injures worms so that they
release internal antigens that are normally concealed inside the parasite.
Results from this study also confirmed our previous finding that plasma CIC
levels do not increase after treatment of LF in persons who develop moderate AEs (13).
This finding suggests that AEs after LF treatment are not caused by CIC. The
complement cascade (classical pathway) modulates pro-inflammatory effects of CIC
(38). Activation of the classical complement cascade leads to decreased C3 and C4,
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whereas activation of the alternative pathway (AP) leads to decreased C3 and factor B
(FB). Our results are most consistent with activation of the AP by parasite antigens, as C3
and FB decreased in individuals with moderate AEs while there was no change in C4
levels. The RNA-seq data also supports the AP hypothesis, because expression of CFP
(complement factor properdin- a positive regulator and initiator of the AP) significantly
increased post-treatment in individuals with moderate AEs (adjusted P-value 0.001,
DESeq2). In contrast, expression of C4B (basic form of C4, part of the classical pathway)
significantly decreased (adjusted P-value 0.04, DESeq2) post-treatment in individuals
with moderate AEs. Additionally, IFN-γ and TNF-α are known to induce FB synthesis
(39). This could account for the inconsistent FB levels post-treatment in individuals with
moderate AEs, because both IFN-γ and TNF-α increased in these individuals; the positive
stimulus of these cytokines may have counteracted decreases in FB levels as it was used
in the AP. In summary, many different filarial antigens were transiently released posttreatment, but they did not appear to form CIC or activate the classical complement
cascade.
PBL appeared to respond to the release of filarial antigens by releasing cytokines,
and the cytokine profiles of post-treatment AEs in LF infected individuals are complex.
In our previous study of samples from a treatment trial in Papua New Guinea, we
reported that 16 cytokines increased post-treatment in individuals with moderate AEs
(13), and eight of these cytokines were also increased after treatment in this study (IL1RA, IL-6, IL-10, G-CSF, MCP-1, MIP-1β, TNF-α, and VEGF). It is not surprising that
more cytokines increased in the previous study, because more time-points were sampled.
Also, participants in the Papua New Guinea study had higher blood Mf counts and higher
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rates and severity of AEs than participants in the present study, and this may account for
their stronger cytokine responses. A new finding in this study was the increase in IFN-γ
post-treatment in individuals with moderate AEs. This was supported by the fact that
IRF1 (downstream of IFN-γ) was identified to be an important transcription factor for AE
development. The increase in IL-8 levels paralleled the increase in neutrophils posttreatment in individuals with moderate AEs. Results from this study did not confirm the
finding from the prior Papua New Guinea study that high levels of eotaxin-1 pretreatment are a risk factor for development of post-treatment AEs. Again this discrepancy
may be related to differences in infection intensity between participants in the two
studies. Levels of IL-6 and TNF-α have previously been shown to positively correlate to
levels of Wolbachia DNA in human plasma 48 hours after treatment of LF (40).

Changes in gene expression in PBL in persons who experienced moderate AEs after
treatment.
RNA-seq was performed to better understand changes in leukocyte gene
expression that occur in persons who experienced moderate AEs after treatment. We
identified a distinctive transcriptional signature associated post-treatment moderate AEs
with 783 genes that were differentially expressed (at the P < 10-5 level) in persons who
experienced moderate AEs. In contrast, no gene was differentially expressed at that level
of significance before or after treatment in individuals who did not experience AEs. 95%
of the 783 genes associated with AEs exhibited increased expression post-treatment.
Thus, moderate AEs were primarily associated with upregulation of gene expression and
not with gene suppression. A total of 126 genes were upregulated post-treatment in
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individuals with no AEs at the low stringency P < 0.05 level, but 83% of these genes
were also upregulated post-treatment in individuals with moderate AEs. Thus changes in
gene expression after treatment did not always lead to clinically evident AEs.
The transcriptional signature results are consistent with the hypothesis that
Wolbachia lipoprotein activates TLR2-TLR6 (18, 41), as bacterial lipoproteins can
induce pro-inflammatory responses through TLR2 signaling and NF-κB and STAT1
activation (42). The finding that TLR2 was one of the genes most highly associated with
the development of moderate AEs also supports this hypothesis. Furthermore, LBP was
found to increase post-treatment in plasma from individuals with moderate AEs, and RF
analysis identified LBP (fold change post-treatment) as the best variable for classifying
AE outcome. LBP is an acute-phase protein that is mostly known for its function of
shuttling LPS to TLR4 via CD14. However, it can also shuttle lipoproteins to TLR2 also
via CD14 (43) as would be the case with PAL. CD14 expression was upregulated posttreatment in individuals with moderate AEs, and it had one of the most significant
adjusted P-values (6.4e-26) in the dataset. CD36 is another accessory receptor for the
TLR2-TLR6 heterodimer (44), and this gene was also upregulated post-treatment in
individuals with moderate AEs (adjusted P-value 0.004). The LF AE transcriptional
signature was similar to previously published endotoxin exposure gene expression
profiles further supporting the Wolbachia lipoprotein hypothesis. Since multiple filarial
antigens that are normally not accessible to the immune system are released posttreatment, it is possible that Wolbachia components are released into the host’s
circulation in a similar fashion. Thus we cannot be certain that Wolbachia lipoprotein is
the only or prime trigger for AEs. It is possible that other filarial components can signal
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through TLRs and contribute to the development of AEs, and this might explain why
expression of many other TLRs (TLR1, TLR4, TLR5, TLR6 and TLR8) were upregulated
post-treatment in individuals with moderate AEs. Many different ligands can activate
TLR2, including protozoan ligands such as GPI anchors from Trypanosoma cruzi (45)
and Leishmania major (46). Wolbachia-independent activation of the immune system
causing severe AEs is seen in Loa loa (a filarial worm that lacks Wolbachia (1)) infected
individuals post-treatment suggesting that Wolbachia is not the sole cause of AEs after
anti-filarial treatment. TLR signaling is clearly associated with the development of AEs,
but complement activation has similar downstream effects, and there is considerable
crosstalk between these two pathways (47). Thus both TLR signaling and the
complement AP could be actively involved in the pathogenesis of AEs. Another possible
mechanism for AEs following treatment of LF is that treatment abrogates the normally
dominant Th2 immune responses stimulated by helminth infections that interfere with the
expression and function of TLRs (48). Increased TLR expression and signaling after
treatment may then induce pro-inflammatory Th1 responses causing AEs. Indeed, classic
Th1 cytokines TNF-α and IFN-γ were increased after treatment in people with moderate
AEs.
We did not detect a pre-treatment transcriptional signature that was a significant
risk factor for development of post-treatment AEs. Baseline CFA levels were the best
predictor for moderate AEs in this study, and this was the only variable that was a
significant predictor by logistic regression. CFA levels are correlated with Mf counts and
likely with adult worm numbers, and this result suggests that CFA levels are related to
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the total parasite biomass that can potentially contribute to the development of AEs after
treatment.

Genes upregulated post-treatment in individuals with AEs.
An important finding from this study was that post-treatment AEs in LF-infected
individuals are associated with upregulation of hundreds of genes. A prioritized list of the
top 15 genes important for the development of AEs is listed above in Table 2. These
genes and their associated pathways may provide insight into the pathogenesis of AEs. In
addition to the TLR pathway, Notch, NF-κB and IL-1 signaling were common themes.
Four of the top 15 genes (RBPJ, TLR2, ALDH1A2 and APLP2) are involved in
TLR/Notch signaling. The Notch pathway is involved in development and is conserved
from Drosophila to mammals. RBPJ is involved in the crosstalk between TLR and Notch
signaling that is thought to help fine-tune the immune response through negative and/or
positive feedback (Supplemental Figure 4) (49). NF-κB is another downstream pathway
of Notch signaling, and three of the top 15 genes (PELI1, TLR2 and LTBR) are involved
in NF-κB signaling. TLR2 is a receptor for the canonical NF-κB pathway, and PELI1 is
involved in intracellular downstream signaling. The canonical pathway results in the
release of pro-inflammatory cytokines, such as IL-6 and TNF-α. Thus, activation of this
pathway is consistent with the cytokine profiles individuals who experienced moderate
AEs after treatment. Interestingly, lymphotoxin beta receptor (LTBR) stimulation has
been shown to enhance the LPS-induced expression of IL-8 via the combined action of
NF-κB and IRF1 (50), and this is consistent with our results. Finally, IL-1 is clearly
associated with the development of AEs. IL-1RAP was one of the top 15 genes identified
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by RF, and this gene is one of two co-receptors for IL-1. Additionally, expression of the
second co-receptor IL-1R1 was increased post-treatment in individuals with AEs. Both
expression (this study) and plasma levels (our prior study (13)) of IL-1β increased after
treatment in individuals with AEs. Inhibitors of the IL-1 pathway were also upregulated
post-treatment in individuals with AEs. This included both increased expression and
protein levels of IL-1RA and increased expression of the IL-1β decoy receptor IL-1R2.
These results illustrate the importance of the balance between the pro-inflammatory
effects of IL-1β and the anti-inflammatory effects of IL-1RA for AE development.

Limitations of the study.
One limitation of this study was that the RNA-seq was performed on mixed PBL
samples. This makes it difficult to separate the effects of altered gene expression from the
effects of changing cell type proportions. Separating different types of leukocytes was not
feasible, because the samples were collected in rural Côte d’Ivoire and processed in a
simple field lab. On the other hand, this study provides insight into the pathogenesis of
post-treatment AEs. Additionally, it was possible to estimate the different cell subtypes
present in PBLs using the RNA-seq data, so we could associate changes in gene
expression with altered cell types to decrease the chance that the former was a directly
result of the latter. For example, if the post-treatment AE transcriptional signature had
been similar to a neutrophil gene expression profile it could have been caused by the
increasing proportion of neutrophils post-treatment and not due to specific neutrophil
activation during AEs. Another limitation was that we did not study an untreated control
group, because it would have been unethical to withhold treatment from infected
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individuals. For the cytokine analysis we did not correct for multiple comparisons,
however, the results are generally consistent with our previous findings (13), and this
increases our confidence in the results. Based on the standard significance level of 0.05,
approximately 3 differences would be expected to be significant by chance for 54 tests
(27 cytokines measured pre- and post-treatment in two AE groups), whereas 17
comparisons were significant at the 0.05 level in this study. The semi-quantitative
Filariasis Test Strip (FTS) was used to assay CFA in the field, whereas a quantitative
ELISA was used to measure CFA levels in the laboratory setting in this study. Newer
studies have demonstrated that tests that detect LF CFA (including FTS) can cross-react
with L. loa antigens that circulate in blood from a subset of individuals with heavy
infections (51), and with biological samples from animals infected with L. loa and
Onchocerca ochengi (52, 53). This cross-reactivity was not a concern for this study
because L. loa is not endemic to Côte d’Ivoire, and the area of Côte d’Ivoire where the
study was conducted is non-endemic for O. volvulus.
In future studies it would be interesting to measure Wolbachia DNA in pre and
post-treatment samples from individuals with AEs after treatment of LF and
onchocerciasis to try to correlate bacterial DNA release with host expression profiles
post-treatment. Wolbachia DNA has been shown to increase post-treatment in individuals
with AEs after treatment of LF (14). Additionally, peak Wolbachia DNA levels have
been shown to be correlated with AE reaction scores in individuals treated with DEC or
IVM for onchocerciasis (54).
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Conclusions.
This study included first global RNA-seq analysis of PBLs from LF-infected
individuals, and it has provided novel insights into the pathogenesis of a clinically
relevant problem. The samples were ideal for studying AEs after LF treatment, because
each post-treatment sample was paired with a pre-treatment sample from the same
individual. This internal control improved our ability to study the AE phenotype in
humans. AEs represent a significant challenge for the global program to eliminate LF,
and the fear of AEs in communities receiving MDA is a main factor that reduces
compliance (25). Minimizing the impact of AEs has therefore been identified as a key
component for successful MDA programs (25). More than 850 million individuals have
been treated as part of GPELF, and a significant percentage of these individuals
experience AEs.
This study has also provided a framework for investigating the host responses
associated with severe AEs that occur after treatment of other filarial worms such as O.
volvulus and L. loa. Treatment of other, more familiar infections can also result in severe
AEs that are caused by host responses to dying pathogens. This Jarisch-Herxheimer
reaction occurs after antibiotic treatment of spirochetal infections such as syphilis, Lyme
disease, leptospirosis, and relapsing fever, and it is also hypothesized to be caused by the
release of bacterial lipoproteins that activate TLR2 (55). The transcriptomic response
during the Jarisch-Herxheimer reaction has not been studied, so the dataset from this
study could provide a valuable starting point for research on this related clinical problem.
To recap our major findings, this study has provided new insights regarding the
pathogenesis of post-treatment AEs in LF-infected individuals. Our results are consistent
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with the hypothesis that a Wolbachia lipoprotein triggers AEs by binding to TLR2-TLR6,
but other uncharacterized filarial antigens might also play a role. Since TLR, NF-κB, and
TNF pathways are involved, these pathways could potentially be targeted to prevent or
treat AEs after LF treatment. We also found that high pre-treatment CFA levels were the
best predictors of post-treatment AEs. This finding could be relevant for treatment-naïve
areas with high LF infection prevalence and intensities. Individuals with high CFA levels
pre-treatment (assessed with the FTS (56)) could be offered non-steroidal antiinflammatory medications together with antifilarial medications for home management of
moderate or severe AEs. However, a positive FTS from an individual who resides in or
has traveled to an area that is also endemic for L. loa needs to be interpreted with caution
due to the issues of cross-reactivity mentioned above. Information from this study should
allow program managers and drug distributors to reassure populations and communicate
to them that AEs experienced after LF treatment are transient and caused by host
responses to dying or injured parasites.
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Figure 3.1: Filarial antigens increase post-treatment in individuals with moderate adverse events
(AEs).
Circulating filarial antigen (CFA) levels increased significantly more post-treatment in
individuals who experienced moderate adverse events (mod AEs) compared to individuals with
no AEs (P < 0.05 by Kruskal-Wallis) (n=62 with no AEs, n=24 with mild AEs, n=9 with
moderate AEs). Boxes indicate the interquartile range (25th and 75th percentile of data
distribution), and horizontal lines within the boxes are median values. The whiskers show 95%
confidence intervals around the median values.
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Figure 3.2: Levels of complement components and lipopolysaccharide binding protein (LBP)
pre- and post-treatment (n=9 with moderate adverse events (AEs), n=9 with no AEs).
[A] Complement component 3 (C3) significantly decreased post-treatment in individuals with
moderate AEs (*P = 0.03 by paired t-test). [B] Complement component 4 (C4) did not change
with treatment in either AE group. [C] Complement Factor B (FB) did not change with treatment
in either AE group. [D] LBP levels significantly increased post-treatment in individuals with
moderate AEs (***P = 0.00007 by paired t-test).
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Figure 3.3: Post-treatment fold changes for 12 cytokines in nine participants who experienced
moderate AEs and in nine participants who had no AEs.
Levels of IL-8, MCP-1, VEGF, TNF-α, MIP-1β, G-CSF and IFN-γ significantly increased posttreatment in individuals with moderate AEs, and levels of IL-1RA, IL-6, IL-10, MIP-1α and IP10 increased significantly post-treatment in individuals with moderate AEs and in individuals
with no AEs (*P < 0.05, **P < 0.001 by Wilcoxon signed-rank tests). IL-1RA, IL-6 and IL-10
increased more in individuals with moderate AEs (*P < 0.05 by Mann-Whitney U tests).
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Figure 3.4: Overall expression patterns and enrichment pre- and post-treatment (n=9 with
moderate adverse events (AEs), n=9 with no AEs).
[A] Sample clustering (Euclidean distance) based on gene expression profiles across all genes.
Post-treatment AEs (red) samples are significantly overrepresented in the fourth group (bolded,
P < 0.0001, binomial distribution). Treatment arms; A: albendazole (ALB), IA: ivermectin
(IVM) and ALB, IDA: IVM, diethylcarbamazine and ALB. [B] Principal component analysis of
paired samples. Post-treatment AEs samples (red) are significantly different from their pretreatment controls (yellow) (P = 0.005 by PERMANOVA). No other differences between the
four groups are significant. [C[/[D] Expression plots comparing pre- and post-treatment gene
expression in individuals with moderate AEs [C] and individuals with no AEs [D]. Red dots
represent genes significantly upregulated post-treatment, and blue dots are genes significantly
upregulated pre-treatment (P < 10-5 for the AE group [C], and P < 0.05 for the no AE group [D]
from DESeq2). [E] Overlap between the genes upregulated pre- and post-treatment between the
two AE groups.
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Figure 3.5: Estimated leucocyte subtypes (CIBERSORT) for the two adverse events (AEs)
groups.
[A] Percent change post-treatment of leukocyte subtypes. Estimated lymphocytes decreased
more and estimated neutrophils increased more post-treatment in individuals with moderate AEs
(n=9) compared to individuals with no AEs (n=9). [B] Estimated leukocyte proportions pretreatment. Individuals that did not develop AEs (n=9) had higher levels of estimated memory B
cells pre-treatment compared to individuals that developed moderate AEs (n=9). *P < 0.05 by
Mann-Whitney U tests.
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Figure 3.6: qRT-PCR validation of RNA-seq data.
Post-treatment fold change of the top eight genes identified by random forest analysis. Seven of
the genes (DIP2B, ZCCHC6, PELI1, FNDC3B, TLR2, LTBR and NT5C2) significantly increase
only in individuals with moderate adverse events (AEs) (n=8) compared to individuals with no
AEs (n=9). *P < 0.05, **P < 0.001 by t-tests. HPRT1 is a housekeeping gene that should not
change with treatment in either AE group.
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Table 3.1: Clinical characteristics of the nine individuals with moderate adverse events (AEs)
after LF treatment.
ID

Treatment arm

Sex

Age

Mf/mLA

5
6
7
8

IVM/ALB
IVM/ALB
IVM/DEC/ALB
IVM/DEC/ALB

M
M
F
M

35
60
32
48

349
700
264
660

Objective AEsB
(Pre and Post)C
37.0 - 38.5
120/70 - 100/60
35.7 - 38.0
36.7 - 38.2

9

IVM/DEC/ALB

M

52

229

36.3 - 37.4

10

IVM/DEC/ALB

M

34

308

37.0 - 37.8

11

IVM/ALB

M

29

560

37.5 - 38.5

12

IVM/DEC/ALB

M

69

503

170/90 - 120/80

17

IVM/DEC/ALB

M

32

79

37.0 - 37.9

A

Subjective AEsD
HA(1), fever(1)
HA(1), N/V(1)
Fever(2), joint pain(1)
HA(1), fever(1), rash(1),
cough(1)
HA(2), fever(2), rash(1),
joint pain(1), fatigue(1)
HA(1), fever(1), joint
pain(1), muscle pain(1),
fatigue(1)
Fever(1), rash(1), muscle
pain(1)
N/V(1), rash(2), dark
urine(1), cough(1), joint
pain(1)
N/V(2), dyspnea(2)

Mf/mL: microfilaria per mL of blood. BObjective AEs: increase of at least 0.8°C to at least
37.4°C post-treatment (axillary temperature), or a decrease of at least 20mmHg systolic pressure
post-treatment. CPre- and post-treatment temperatures or blood pressures are shown. DSubjective
AEs: symptoms that the patient reported during the review of systems questions. Grades: 1; mild
symptom and patient could attend work or school. 2; patient could not attend school/work. HA:
headache, N/V: nausea/vomiting.
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Table 3.2: Top 15 genes associated with development of moderate adverse events in LF patients
after treatment as identified by random forest analysis.
Gene

Gene Description

DIP2B
ZCCHC6
RBPJ
PELI1
FNDC3B
TLR2
LTBR
NT5C2
KIAA1551
ALDH1A2
ZSWIM6
APLP2
MYLIP
FGD4
IL1RAP

Disco interacting protein 2 homolog B
Zinc finger CCHC-type containing 6
Recombination signal binding protein for Ig kappa J region
Pelino E3 ubiquitin protein ligase 1
Fibronectin type III domain containing 3B
Toll like receptor 2
Lymphotoxin beta receptor
5’-nucleotidase, cytosolic II
KIAA1551
Aldehyde dehydrogenase 1 family member A2
Zinc finger SWIM-type containing 6
Amyloid beta precursor like protein 2
Myosin regulatory light chain interacting protein
FYVE, RhoGEF and PH domain containing 4
Interleukin 1 receptor accessory protein like 2
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Mean Decrease
in Accuracy
3.30
3.18
3.07
2.99
2.95
2.79
2.65
2.57
2.32
2.08
1.97
1.95
1.95
1.92
1.90

Table 3.3: Logistic regression and random forest analysis of sex, age, treatment arm and
baseline infection parameters on the development of moderate adverse events.
Logistic Regression Model
Variable
B
Odds ratio P-value
Constant
-4.79
0.006
Sex
-0.24
0.79
0.878
Age
0.03
1.03
0.390
Treatment armA
IDA
0.54
1.72
0.558
ALB
-19.28
0.00
0.998
Mf/mL
0.00
1.00
0.753
CFA
0.02
2.69B
0.022
A

Random Forest
Mean Decrease in Accuracy
-2.82
-0.94
4.33
-2.82
11.57

The coefficients for treatment arms are contrasts with the standard treatment, ivermectin (IVM)
plus albendazole (ALB). IDA: IVM, diethylcarbamazine (DEC) and ALB. BReported odds ratio
for CFA (circulating filarial antigen) is for an increase of 50 ng/mL, because the range of CFA
concentrations was wide (7-700 ng/mL).
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0.80

CIC Level (ug/mL AHG)

0.70
0.60
0.50
Pre

0.40

Post

0.30
0.20
0.10
0.00
No AEs (n=33)

Moderate AEs (n=8)

Supplemental Figure 3.1: Circulating immune complex levels.
Mean circulating immune complex (CIC) levels ± standard error pre and post-treatment in
individuals with no adverse events (AEs) (n=33) and individuals with moderate AEs (n=8).
There was no significant difference between pre- and post-treatment values within the two AE
groups (Wilcoxon signed-rank test), or between the two AE groups (Mann-Whitney U tests).
AHG: aggregated human gamma globulin.
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TLR$signaling$

NFkB$
MAPK3$
TNF$

JAK/STAT$
Red:"KEGG"
Black:"individual"Genes"
Blue:"Transcrip3on"Factors"

Supplemental Figure 3.2: Overview of TLR signaling.
TLR signaling pathway with highlighted upregulated genes in black (based on DESeq2 analysis)
and upregulated KEGG pathways (based on WebGestalt analysis) in red. Overrepresented
transcription factors (based on i-CisTarget analysis) are in blue.
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Supplemental Figure 3.3: Estimated leukocyte subtypes post-treatment.
Percent change post-treatment of leukocyte subtypes in people with and without adverse events
(AEs). T cells (CD4 naïve) decrease more and neutrophils increase more post-treatment in
individuals with AEs (n=9) compared to individuals with no AEs (n=9). *P < 0.05, ** P < 0.01
by Mann-Whitney U tests.
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Supplemental Figure 3.4: TLR and Notch.
Crosstalk between the TLR signaling pathway and the Notch pathway. Expression and/or
function of various components of the Notch pathways could be regulated by TLR signaling.
Conversely, Notch pathway components positively or negatively modulate TLR-activated
transcriptional, translational, and metabolic programs to finetune outcomes of immune responses
Figure and text from Shang Y, Smith S, and Hu X. Role of Notch signaling in regulating innate
immunity and inflammation in health and disease. Protein Cell. 2016;7(3):159-74
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Supplemental Table 3.1: Metadata for all 95 individuals including which samples were used for
all the experimental tests.
Metadata

Qualitative/quantitative data collected per individual
Western
CIC
C3/C4
RNABlot
elisa
and FB
LBP
Cytokines
seq

Mf/mL

AEB
group

m

64

0

yes

no

no

no

no

no

no

34

m

56

0

yes

no

no

no

no

no

no

4

25

m

133.5

0

yes

no

no

no

no

no

no

422102

1

32

m

115

0

yes

no

no

yes

yes

yes

yes

422047

1

23

m

112

1

yes

no

no

no

no

no

no

422121

1

23

m

180

0

yes

no

no

no

no

no

no

422111

4

39

m

463.5

0

yes

no

no

no

no

no

no

412415

4

35

m

59.5

0

yes

no

no

no

no

no

no

422041

4

70

f

290

1

yes

no

no

no

no

no

no

422107

1

70

m

122

1

yes

no

no

no

no

no

no

412435

4

18

m

217

1

yes

no

no

no

no

no

no

422032

2

33

m

80

0

yes

no

no

no

no

no

no

412464

4

34

m

317

0

yes

no

no

yes

yes

yes

yes

412407

1

33

m

91.5

1

yes

no

no

no

no

no

no

10-4614

1

30

m

629

0

yes

no

no

no

no

no

no

10-4500

2

26

m

81

0

yes

no

no

no

no

no

no

422074

1

45

m

88

0

yes

no

no

no

no

no

no

422024

2

32

m

55

0

yes

no

no

no

no

no

no

412440

1

18

m

100.5

0

yes

no

no

no

no

no

no

412482

2

56

m

109

1

yes

no

no

no

no

no

no

422115

2

45

m

115.5

0

yes

no

no

no

no

no

no

412447

2

55

m

78.5

0

yes

no

no

no

no

no

no

422117

2

50

f

110

0

yes

no

no

no

no

no

no

422012

4

61

m

68

0

yes

no

no

no

no

no

no

422026

2

29

m

95

0

yes

no

no

no

no

no

no

412431

1

36

m

86.5

1

yes

no

no

no

no

no

no

412446

1

50

f

283.5

0

yes

no

no

no

no

no

no

412473

4

41

m

102.5

0

yes

no

no

yes

yes

yes

yes

422034

2

62

m

210

0

yes

no

no

no

no

no

no

412463

1

45

f

119.5

1

yes

no

no

no

no

no

no

422078

4

52

m

229

2

yes

no

no

yes

yes

yes

yes

412455

4

24

m

53.5

1

yes

no

no

no

no

no

no

Treatment
armA

Age

422046

2

24

422108

1

412413

Study ID

Sex

CFA
EIA

120

422093

4

23

m

106.5

0

yes

no

no

no

no

no

no

422070

2

67

f

94

0

yes

no

no

no

no

no

no

412401

2

55

m

58.5

0

yes

no

no

no

no

no

no

10-4588

2

40

m

270.5

0

yes

no

no

no

no

no

no

422100

4

48

m

69.5

1

yes

no

no

no

no

no

no

412470

2

50

m

220

0

yes

no

no

no

no

no

no

422099

1

25

m

289.5

0

yes

no

no

yes

yes

yes

yes

412414

2

55

m

72.5

0

yes

no

no

no

no

no

no

422128

1

35

m

170.5

0

yes

no

yes

no

no

no

no

412434

2

65

m

703

0

yes

no

yes

no

no

no

no

422075

2

44

m

180.5

0

yes

no

yes

yes

yes

yes

yes

422112

4

35

m

274

1

yes

no

no

no

no

no

no

422079

2

50

m

968.5

0

yes

no

yes

no

no

no

no

422058

4

22

m

329

1

yes

no

no

no

no

no

no

412457

4

34

m

307.5

2

yes

no

yes

yes

yes

yes

yes

10-4651

1

36

m

106

0

yes

no

yes

no

no

no

no

422122

4

32

m

231.5

0

yes

no

yes

no

no

no

no

422125

4

64

m

79

0

yes

no

yes

no

no

no

no

412449

4

40

f

227

0

yes

no

yes

no

no

no

no

422028

4

65

m

70

0

yes

no

yes

no

no

no

no

422082

4

32

m

78.5

2

yes

no

no

yes

yes

yes

yes

412422

1

31

m

74

0

yes

no

yes

no

no

no

no

422083

1

62

m

611.5

0

yes

no

yes

no

no

no

no

422031

1

31

m

291

0

yes

no

yes

no

no

no

no

10-4698

2

32

m

518.5

0

yes

no

yes

no

no

no

no

422060

1

40

m

66

1

yes

no

no

no

no

no

no

422065

2

57

m

171

0

yes

no

yes

no

no

no

no

10-4536

1

19

m

151

0

yes

no

yes

no

no

no

no

422048

2

40

m

132

0

yes

no

yes

no

no

no

no

422144

2

39

m

575

0

yes

no

yes

yes

yes

yes

yes

412408

2

31

f

69.5

0

yes

no

yes

no

no

no

no

412467

1

52

m

240

0

yes

no

yes

no

no

no

no

412453

2

27

m

255

0

yes

no

yes

no

no

no

no

412423

2

25

m

221

1

yes

no

no

no

no

no

no

422080

1

28

m

131

1

yes

no

no

no

no

no

no

422126

2

32

m

444.5

0

yes

no

yes

no

no

no

no

412428

1

31

m

292.5

1

yes

no

no

no

no

no

no

412469

4

18

f

265

1

yes

no

no

no

no

no

no

422091

1

35

m

384

1

yes

no

no

yes

yes

yes

yes

121

412441

1

24

m

450

0

yes

no

yes

no

no

no

no

10-4681

4

35

m

165

1

yes

no

no

no

no

no

no

422094

1

26

m

423.5

0

yes

no

yes

no

no

no

no

412442

2

46

f

151.5

0

yes

no

yes

no

no

no

no

412426

2

18

f

307

0

yes

no

yes

no

no

no

no

422076

1

35

m

348.5

2

yes

yes

yes

yes

yes

yes

yes

412476

1

35

m

261

1

yes

no

no

no

no

no

no

412468

1

23

f

466.5

0

yes

no

yes

yes

yes

yes

yes

08-2665

4

32

m

222

1

yes

no

no

no

no

no

no

412458

2

24

m

230

1

yes

no

no

no

no

no

no

412411

1

29

m

560.5

2

yes

yes

yes

yes

yes

yes

yes

06-4282

4

39

m

1498

0

yes

no

yes

no

no

no

no

412485

4

47

m

590

0

yes

no

yes

no

no

no

no

412462

4

33

m

246

0

yes

no

yes

no

no

no

no

422030

4

20

m

101

0

yes

no

yes

no

no

no

no

422036

4

63

m

142

1

yes

no

no

no

no

no

no

422098

1

30

m

144.5

0

yes

no

yes

yes

yes

yes

yes

422134

1

60

m

700

2

yes

yes

yes

yes

yes

yes

yes

422087

2

35

m

860

0

yes

yes

yes

no

no

no

no

412412

4

69

m

503

2

yes

yes

yes

yes

yes

yes

yes

422089

4

30

f

263.5

2

yes

yes

yes

yes

yes

yes

yes

412452

2

25

m

944

0

yes

yes

yes

no

no

no

no

422116

4

51

m

328.5

1

yes

yes

no

no

no

no

no

422077

4

48

m

659.5

2

yes

yes

yes

yes

yes

yes

yes

A
B

Treatment arm: 1=ALB/IVM, 2=ALB, 4=ALB/IVM/DEC

AE group: 0=no AEs, 1=mild AEs, 2=moderate AEs

122

Supplemental Table 3.2: Characteristics of each adverse event (AE) case and matched control
with no AEs.
ID of AE case Characteristics
Sex
5
Age
Mf/mL
Treatment
6
Sex
Age
Mf/mL
Treatment
7
Sex
Age
Mf/mL
Treatment
8
Sex
Age
Mf/mL
Treatment
9
Sex
Age
Mf/mL
Treatment
10
Sex
Age
Mf/mL
Treatment
11
Sex
Age
Mf/mL
Treatment
12
Sex
Age
Mf/mL
Treatment
17
Sex
Age
Mf/mL
Treatment

With AEs
No AEs
Male
Male
35
30
349
145
IVM/ALB
IVM/ALB
Male
Male
60
32
700
115
IVM/ALB
IVM/ALB
Female
Female
32
23
264
467
IVM/DEC/ALB
IVM/ALB
Male
Male
48
39
660
575
IVM/DEC/ALB
ALB
Male
Male
53
41
229
103
IVM/DEC/ALB IVM/DEC/ALB
Male
Male
34
34
308
317
IVM/DEC/ALB IVM/DEC/ALB
Male
Male
29
35
560
384
IVM/ALB
IVM/ALB
Male
Male
69
44
503
181
IVM/DEC/ALB
ALB
Male
Male
32
25
79
181
IVM/DEC/ALB
ALB
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Supplemental Table 3.3: Primer sequences.
Gene

YWAZ
SDHA
ACTB
HPRT1
DIP2B
ZCCHC6
RBPJ
PELI1
FNDC3B
TLR2
LTBR
NT5C2

Forward Primer Sequence

Reverse Primer Sequence

5'- ACT TTT GGT ACA TTG
TGG CTT CAA -3'
5'- TGG GAA CAA GAG
GGC ATC TG -3'
5'- CTC TGG CTC CTA GCA
CCA TGA AGA -3'
5'- TGC AGA CTT TGC TTT
CCT TGG TCA GG -3'
5'- AGT CCT TCT CTA AGC
TCT TC -3'
5'- AAG CTT TGC AGT ATA
GAT CG -3'
5'- AAT TCA ATT TCA GGC
CAC TC -3'
5'- AGG CAA TAA GCA ACA
AAG AC -3'
5'- CAC AGG TTT CTA ATA
TTC AGG C -3'
5'- CTT TCA ACT GGT AGT
TGT GG -3'
5'- CAT TTC TGG AGA TGT
TTC CC -3'
5'- CAG CGA GAT GAT ACT
GAA AG -3'

5'- CCG CCA GGA CAA
ACC AGT AT -3'
5'- CCA CCA CTG CAT
CAA ATT CAT G -3'
5'- GTA AAA CGC AGC
TCA GTA ACA GTC CG -3'
5'- CCA ACA CTT CGT
GGG GTC CTT TTC A -3'
5'- GGT TCC CTG TAA
ACA TAT TGC -3'
5'- TAG ATA TAC AGG
CAA AAG GGG -3'
5'- CTA ATG ATT GTC CAG
GAA GC -3'
5'- GTC ATG AGT ATA TTC
AAC CAC C -3'
5'- CTT GTA TTT TCC ATC
TCG TCC -3'
5'- GGA ATG GAG TTT
AAA GAT CCT G -3'
5'- TAG ATG TTG CCA
GTG ATA GTC -3'
5'- ACA ACT GGT ATA TCT
GGG AC -3'
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Company

KicqStart
Primer Pair ID

IDT

NA

IDT

NA

IDT

NA

IDT

NA

Sigma

H_DIP2B_1

Sigma

H_ZCCHC6_1

Sigma

H_RBPJ_1

Sigma

H_PELI1_1

Sigma

H_FNDC3B_1

Sigma

H_TLR2_1

Sigma

H_LTBR_1

Sigma

H_NT5C2_1

Supplemental Table 3.4: Age and sex distribution in the three adverse events (AEs) groups.
No AEs Mild AEs Moderate AEs P-value
(n=62)
(n=24)
(n=9)
Age
38.5
37.4
43.2
0.58A
Sex (male) 87.1%
87.5%
88.8%
0.99B
A
B

Kruskal-Wallis H test
Chi-squared test
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Supplemental Table 3.5: Upregulated KEGG pathways post-treatment in individuals with
adverse events (WebGestalt analysis).
C
127
167
170
91

O
34
33
29
20

E
6.918
9.097
9.260
4.957

R
4.915
3.628
3.132
4.035

P-Value
2.11E-15
5.25E-11
2.78E-08
5.83E-08

FDR
6.39E-13
7.96E-09
2.81E-06
4.33E-06

167
133
147
66
54
89

28
24
25
16
14
18

9.097
7.245
8.007
3.595
2.941
4.848

3.078
3.313
3.122
4.451
4.760
3.713

7.15E-08
1.53E-07
2.77E-07
3.03E-07
6.98E-07
1.01E-06

4.33E-06
7.74E-06
1.15E-05
1.15E-05
2.35E-05
3.06E-05

67
181
82

14
25
15

3.649
9.859
4.467

3.836
2.536
3.358

1.10E-05
1.38E-05
2.90E-05

0.00030
0.00035
0.00068

123
62
177

19
12
22

3.18E-05
0.00010
0.00022

0.00069
0.00209
0.00423

258
92
55
108
156
110
69
70
50
72
95
131
145

28
14
10
15
19
15
11
11
9
11
13
16
17

1.992
2.794
3.338
2.550
2.236
2.503
2.927
2.885
3.305
2.805
2.512
2.242
2.152

0.00034
0.00041
0.00066
0.00070
0.00077
0.00085
0.00113
0.00128
0.00131
0.00162
0.00179
0.00190
0.00217

0.00602
0.00687
0.01049
0.01055
0.01104
0.01166
0.01492
0.01590
0.01590
0.01889
0.02010
0.02059
0.02270

hsa04010
hsa04620
hsa04210
hsa04066
hsa04670
hsa04071

MAPK signaling pathway
Toll-like receptor signaling pathway
Apoptosis
HIF-1 signaling pathway
Leukocyte transendothelial migratio
Sphingolipid signaling pathway

252
101
138
102
116
118

25
13
16
13
14
14

6.700
3.377
9.641
14.05
3
5.011
2.996
5.883
8.497
5.992
3.758
3.813
2.724
3.922
5.175
7.136
7.898
13.72
6
5.501
7.517
5.556
6.319
6.427

2.836
3.553
2.282

hsa04060
hsa04640
hsa05130
hsa04668
hsa04630
hsa05145
hsa04664
hsa04662
hsa05150
hsa05133
hsa05146
hsa05160
hsa05161

DescriptionA
Osteoclast differentiation
Tuberculosis
Influenza A
Fc gamma R-mediated phagocytosis
NOD-like receptor signaling
pathway
Measles
Phagosome
Leishmaniasis
Legionellosis
NF-kappa B signaling pathway
Epithelial cell signaling in
Helicobacter pylori infection
Chemokine signaling pathway
Salmonella infection
Natural killer cell mediated
cytotoxicity
Inflammatory bowel disease (IBD)
Herpes simplex infection
Cytokine-cytokine receptor
interaction
Hematopoietic cell lineage
Pathogenic Escherichia coli infection
TNF signaling pathway
Jak-STAT signaling pathway
Toxoplasmosis
Fc epsilon RI signaling pathway
B cell receptor signaling pathway
Staphylococcus aureus infection
Pertussis
Amoebiasis
Hepatitis C
Hepatitis B

1.821
2.363
2.129
2.340
2.216
2.178

0.00250
0.00312
0.00325
0.00340
0.00400
0.00467

0.02528
0.03048
0.03079
0.03124
0.03565
0.04045

Geneset
hsa04380
hsa05152
hsa05164
hsa04666
hsa04621
hsa05162
hsa04145
hsa05140
hsa05134
hsa04064
hsa05120
hsa04062
hsa05132
hsa04650
hsa05321
hsa05168

A

Kegg pathway name. C: the number of reference genes in the category. O: the number of genes
in the gene set and also in the category. E: the expected number in the category. R: ratio of
enrichment. P-value: P-value from hypergeometric test. FDR: P-value adjusted by the multiple
test adjustment.
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Supplemental Table 3.6: Enriched transcription factor binding sites in the 744 genes
upregulated post-treatment in individuals with adverse events.
Transcription factor
binding site
STAT1
STAT2
SPI1
STAT3
IRF1
CEBPB

Normalized
enrichment score
7.74
7.23
6.40
4.43
4.24
3.50
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Supplemental Table 3.7: Upregulated KEGG pathways pre-treatment in individuals that did not
develop adverse events (Gene Set Enrichment Analysis).
NAMEA
RIBOSOME
SPLICEOSOME
LEISHMANIA_INFECTION
PROTEASOME
PRIMARY_IMMUNODEFICIENCY
ANTIGEN_PROCESSING_AND_
PRESENTATION
TOLL_LIKE_RECEPTOR_
SIGNALING_PATHWAY
LYSOSOME
MAPK_SIGNALING_PATHWAY
CELL_CYCLE
PARKINSONS_DISEASE
CITRATE_CYCLE_TCA_CYCLE
B_CELL_RECEPTOR_
SIGNALING_PATHWAY
BASE_EXCISION_REPAIR
UBIQUITIN_MEDIATED_
PROTEOLYSIS
ALLOGRAFT_REJECTION
MISMATCH_REPAIR
PATHWAYS_IN_CANCER
GLYCOSYLPHOSPHATIDYLINOSITO
L_GPI_ANCHOR_BIOSYNTHESIS
INTESTINAL_IMMUNE_NETWORK_
FOR_IGA_PRODUCTION
NUCLEOTIDE_EXCISION_REPAIR
PYRIMIDINE_METABOLISM
ASTHMA
PURINE_METABOLISM
ALZHEIMERS_DISEASE
DNA_REPLICATION
AUTOIMMUNE_THYROID_DISEASE
FOCAL_ADHESION
HUNTINGTONS_DISEASE
GRAFT_VERSUS_HOST_DISEASE
ENDOCYTOSIS
APOPTOSIS
ACUTE_MYELOID_LEUKEMIA
OXIDATIVE_PHOSPHORYLATION
RNA_POLYMERASE
T_CELL_RECEPTOR_SIGNALING_
PATHWAY
AMINOACYL_TRNA_BIOSYNTHESIS
VALINE_LEUCINE_AND_
ISOLEUCINE_DEGRADATION

SIZE
87
123
70
44
35

ES
0.6840
0.2979
0.3227
0.3978
0.4164

NES
7.4153
3.8336
3.1892
3.0886
2.8864

NOM P-val
0.0000
0.0000
0.0000
0.0000
0.0000

FDR q-val
0.0000
0.0000
0.0000
0.0000
0.0005

FWER P-val
0.0000
0.0000
0.0000
0.0000
0.0020

69

0.2965

2.8473

0.0000

0.0007

0.0030

91
119
257
124
109
29

0.2470
0.2165
0.1408
0.2026
0.2067
0.3911

2.7722
2.7591
2.6306
2.5813
2.5713
2.5363

0.0000
0.0000
0.0000
0.0000
0.0000
0.0000

0.0014
0.0014
0.0019
0.0020
0.0018
0.0020

0.0070
0.0080
0.0120
0.0140
0.0140
0.0170

74
33

0.2498
0.3695

2.5301
2.4690

0.0000
0.0000

0.0022
0.0027

0.0200
0.0260

133
35
23
321

0.1820
0.3364
0.3872
0.1067

2.4570
2.3948
2.2243
2.2143

0.0000
0.0000
0.0000
0.0000

0.0028
0.0040
0.0103
0.0101

0.0290
0.0440
0.1250
0.1300

24

0.3670

2.1778

0.0000

0.0109

0.1540

46
44
95
26
152
154
36
39
196
169
37
176
85
57
114
29

0.2650
0.2599
0.1809
0.3816
0.1494
0.1454
0.3065
0.2757
0.1191
0.1347
0.2851
0.1402
0.1914
0.2323
0.1613
0.2927

2.1150
2.0353
2.0589
2.3187
2.1568
2.0949
2.1809
2.0175
1.9480
2.0422
2.0825
2.1739
2.0350
2.0824
2.0685
1.9155

0.0000
0.0000
0.0019
0.0020
0.0020
0.0020
0.0020
0.0020
0.0021
0.0021
0.0039
0.0040
0.0040
0.0040
0.0041
0.0043

0.0140
0.0175
0.0164
0.0058
0.0112
0.0148
0.0112
0.0183
0.0254
0.0172
0.0153
0.0106
0.0170
0.0148
0.0163
0.0279

0.2250
0.3240
0.2870
0.0680
0.1710
0.2430
0.1500
0.3550
0.4720
0.3090
0.2550
0.1580
0.3240
0.2550
0.2790
0.5230

106
41

0.1602
0.2754

1.9357
2.1340

0.0058
0.0077

0.0259
0.0126

0.4870
0.1980

44

0.2432

1.9112

0.0080

0.0281

0.5310

A

KEGG pathway. Size: Number of genes in the gene set after filtering out those genes not in the
expression dataset. ES: enrichment score for the gene set; that is, the degree to which this gene
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set is overrepresented at the top or bottom of the ranked list of genes in the expression dataset.
NES: normalized enrichment score; that is, the enrichment score for the gene set after it has been
normalized across analyzed gene sets. NOM P-val: Nominal P-value; that is, the statistical
significance of the enrichment score. The nominal P-value is not adjusted for gene set size or
multiple hypothesis testing; therefore, it is of limited use in comparing gene sets. FDR q-val;
false discovery rate; that is, the estimated probability that the normalized enrichment score
represents a false positive finding. FWER P-val: Familywise-error rate; that is, a more
conservatively estimated probability that the normalized enrichment score represents a false
positive finding.
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Supplemental Table 3.8: Variables in the random forest model (post-treatment fold change).
Variable
Average Mean Decrease in Accuracy
LPS binding protein (LBP)
9.85
Complement component 3 (C3)
-0.66
Circulating immune complexes (CIC)
-2.35
Complement Factor B (FB)
-2.92
Circulating filarial antigen (CFA)
-4.20
Complement component 4 (C4)
-5.01
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Chapter 4:
Discussion, future directions and conclusion
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Preface
This chapter was written by BJA. Comments from GJW and PUF were incorporated into the
final version, presented here.
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4.1

Comparison of the two sample cohorts: Papua New Guinea and Côte d'Ivoire.
Researchers and clinician scientists have been interested in understanding the
adverse events (AEs) that occur after lymphatic filariasis (LF) treatment for decades, but
the pathogenesis has been difficult to define. We decided to study AEs using human
samples that were collected in different LF treatment trials in Papua New Guinea and
Côte d'Ivoire. The main findings from the Papua New Guinea pilot study (1) showed that
various filarial components such as antigen and DNA are released post-treatment in
individuals with AEs. Contrary to our hypothesis and a previously published paper (2),
we did not observe an increase in circulating immune complexes (CICs) post-treatment in
individuals with AEs. Additionally, we found that the cytokine response during AEs is
complex with a large number of cytokines being released after treatment. The cytokine
response observed in individuals with AEs was similar to the cytokine response after
endotoxin exposure, and was therefore consistent with Wolbachia exposure. However,
based on this study we were unable to determine what filarial or Wolbachia components
were responsible for the immune activation, and if the host response was caused by
phagocytosis of filarial/Wolbachia components, by direct interaction between foreign
antigens and host cell surface receptors or by a combination of both. In order to delineate
the immune response during AEs, we decided to look at the host gene expression before
and after treatment in leucocytes from individuals with and without AEs.
In order to address this question we took leverage of a clinical trial conducted in
Côte d'Ivoire (Clinicaltrials.gov NCT # 02974049) to collect plasma and buffy coat
samples. The RNA-seq analysis of RNA extracted from pre- and post-treatment buffy
coat samples identified a significant transcriptional signature of post-treatment AEs in
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LF-infected individuals. TLR and NF-κB signaling were overrepresented, and overall the
gene expression profile was consistent with the hypothesis that the Wolbachia
lipoprotein, PAL, signals through TLR2 (3). We also established that LPS Binding
Protein (LBP) increases more post-treatment in individuals with AEs, and this finding
also supports the Wolbachia/TLR2 signaling pathway. These new findings are presented
schematically in Figure 4.1A. We confirmed the majority of the cytokine results from the
Papua New Guinea pilot study. Additionally, we found that the classical complement
pathway does not appear to be activated during AEs, whereas the alternative complement
pathway is possibly involved in the development of AEs. This was supported by the fact
that we again did not observe an increase in CIC post-treatment in individuals with AEs.
We assed Wolbachia DNA levels in plasma by qPCR, but obtained results that were
contradictory to published literature. Previously published studies used nested PCR to
measure Wolbachia DNA in human plasma (4), but we feel that this method is prone to
contamination when using field samples, so we did not attempt this approach.
The Papua New Guinea study cohort was small with a total 24 enrolled
participants, but it was a pharmacokinetic study so blood samples were available from
many time points from pre-treatment up until 72 hours post-treatment (5). This repeatedsampling from the same individuals was helpful to examine the kinetics of cytokine
release, and to assess when filarial components were detectable in the host blood. We
found that 24 hours post-treatment was a good time-point to measure cytokines and
filarial components because many cytokines peaked at around this time and CFA levels
were increased. Additionally, AEs peak at around 24-48 hours post-treatment (6-10). For
the larger Côte d'Ivoire trial we therefore decided to collect samples pre-treatment and at
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24 hours post-treatment. The Papua New Guinea pharmacokinetic trial was conducted in
2014, and a collaborator had collected the blood samples. Our AE study was not the main
focus of the pharmacokinetic trial, and this meant that we only had access to a very
limited volume of plasma, and buffy coat samples had not been collected at all. For the
larger clinical trial in Côte d'Ivoire I was in the field during pre-screening and for over
one month during the enrollment period. I collected samples and taught the team how to
process the blood to separate the buffy coat from the plasma. I also organized the clinical
data assessment (vital signs, review of systems, and AE data) for each individual, and
made a database with all this information. This effort resulted in paired pre- and posttreatment samples from over 120 treated individuals, and detailed clinical information for
each person. This dissertation was unique in the sense that I was in a position to be
involved in all the stages of the project; from pre-screening potential study subjects and
preparing for the clinical trial, to enrolling and treating infected individuals in an endemic
country, and finally conducting the bioinformatics analysis and additional laboratory
experiments using the human samples that had been collected. Very few individuals in
the Côte d'Ivoire trial developed moderate AEs. We selected a subset of participants to
include in our study, and ended up with a cohort of 95 individuals including nine
individuals with moderate AEs, 24 with mild AEs and 62 with no AEs. The AE rate was
much higher in the Papua New Guinea cohort where out of the 24 participants 7
developed moderate AEs, 12 developed mild AEs and 5 had no AEs (5). This drastic
difference in AE rate and severity was likely due to the fact that the Papua New Guinea
individuals had much higher baseline levels of Mf compared to the individuals from the
Côte d'Ivoire cohort.
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4.2

Circulating immune complexes and the classical complement pathway are not
involved in the development of AEs.
One of the hypotheses going into the project was that CIC formed after treatment
could trigger AEs, however, we did not see an increase in CIC in the pilot study or the
larger clinical trial study. This was surprising because a previous study had concluded
that CIC increase post-treatment (2). An explanation for this discrepancy could be that
CIC were measured much later after treatment in the previous study (7 days posttreatment), whereas we measured CIC at 24 hours post-treatment in the Côte d'Ivoire
cohort and up until 72 hours post-treatment in the Papua New Guinea cohort. It takes
time for the immune system to generate antibodies, so perhaps CIC form later posttreatment, but it would be difficult to attribute AEs that peak at 24 hours post-treatment to
CIC that are formed multiple days after treatment. A 12-day course of DEC treatment
was used in the previously published study, whereas we only treated participants once.
The longer treatment regimen could also have led to more CIC formation.
On the other hand, the CIC results agree with the complement data, because the
classical complement cascade does not appear to be involved in the development of AEs,
because C4 levels did not change post-treatment. CIC are part of the initial stage of the
classical pathway, and can bind to the C1-complex to activate the pathway (11). Whereas
the classical complement pathway recognizes and is activated by antigen-antibody
complexes, the alternative pathway is much less stringent in its recognition requirements.
In the alternative pathway spontaneous hydrolysis of C3 allows C3b to covalently attach
to a wide range of substrates, including endotoxin and bacterial polysaccharides (12). The
alternative complement cascade is not known to be activated by bacterial lipoproteins,
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such as Wolbachia PAL. However, one could easily imagine that as the parasites die and
disintegrate post-treatment, a subset of the many released filarial and Wolbachia antigens
could act as substrates for the promiscuous C3b, and thereby activate alternative
complement pathway.

4.3

An allergy-like host response does not appear to be involved in the development of
AEs.
It is well established that prominent eosinophilia and elevated serum IgE levels
are common features of human LF infections (13). It is therefore conceivable that an
allergy-type host response could be involved in the development of post-treatment AEs,
because infected individuals are poised for such an immune reaction. Mast cells,
basophils and eosinophils are essential effector cells in allergic inflammation (14). In
order to monitor for an allergic response we measured histamine, a main effector of
basophils and mast cells, and four different eosinophil granule proteins. Histamine was
measured in 18 individuals (9 with moderate AEs, and 9 with no AEs) pre-treatment and
24 hours post-treatment from the Côte d'Ivoire study cohort. Unfortunately only two
samples had histamine levels over the detection limit of the assay, and both of those
samples were pre-treatment. Four eosinophil granule proteins were measured: major
basic protein (MBP), eosinophil cationic protein (ECP), eosinophil derived neurotoxin
(EDN) and eosinophil peroxidase (EPO). For the eosinophil granule assays four
individuals from the Papua New Guinea cohort were selected (two with moderate AEs
and two with no AEs) and samples from 13 time-points from pre-treatment until 72 hours
post-treatment were tested. The samples were shipped to the Nutman laboratory at the
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NIH where the assays were performed. MBP, ECP and EDN were detected in all
samples, whereas EPO was undetectable in all the samples. With this very limited sample
set no differences were observed between the two AE groups, and levels of MBP, ECP
and EDN did not change much after treatment (Dr. Thomas Nutman, personal
communication). In onchocerciasis eosinophil granule proteins are released after
eosinophils attach to the Mf by an adherence reaction (15). O. volvulus Mf reside in the
skin (16), and it is unlikely that a similar eosinophil reaction occurs in the blood stream
where W. bancrofti Mf are found.
For the two main clinical trials described in this thesis; the pharmacokinetic study
in Papua New Guinea and the larger clinical trial in Côte d'Ivoire, we were unable to
complete white blood cell differential analysis for the enrolled subjects. However, in
2016 our group conducted a pharmacokinetic study in Côte d'Ivoire (Clinicaltrials.gov
NCT # 02845713) (17), as briefly described in chapter 3. For this study we performed
white blood cell differentials for all enrolled subjects pre-treatment and at 24 and 48
hours post-treatment. We did not observe any significant change in eosinophil numbers
post-treatment, and there was no significant difference in eosinophil counts/percentages
pre- or post-treatment between individuals with and without AEs. Half of the individuals
in the pharmacokinetic study were uninfected, so we were able to confirm that at baseline
individuals infected with LF have significantly higher eosinophil counts (mean
approximately 600 eosinophils/uL) compared to uninfected individuals (mean
approximately 300 eosinophils/uL). Based on this limited data we are unable to confirm
or reject the hypothesis that a type IV immune response is involved in the development of
post-treatment AEs in LF-infected individuals.
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4.4

Current hypothesis: a range of filarial and Wolbachia antigens are released after
treatment, and these activate the host immune system resulting in AEs.
We have shown that multiple filarial components, including a range of antigens
and DNA, are released within hours after treatment, and that individuals with AEs have
higher levels of these parasite components in their blood. We have also shown that serum
levels of many cytokines increase after treatment, and most of these only increased in
individuals with AEs. This cytokine profile is complex with some cytokines peaking
within just hours after treatment (IL-12 and IL-17A); others only increase days after
treatment (IL-7) and some remain elevated for an extended period of time (IL-6, IL-10,
MIP-1β and IL-8). Finally, we have assessed the pathogenesis of host responses during
AEs by examining gene expression profiles of leucocytes. The most obvious functional
enrichments post-treatment in individuals with AEs were the TLR and NF-κB signaling
pathways. This included upregulation of six different TLR genes (TLR1, TLR2, TLR4,
TLR5, TLR6 and TLR8), signifying the diverse nature of possible immuno-stimulatory
signals post-treatment. This is because each TLR recognizes specific ligands: triacylated
lipoproteins (TLR1-TLR2), diacylated lipoproteins (TLR2-TLR6), LPS (TLR4), flagellin
(TLR5), and ssRNA (TLR8) (18). Furthermore, many additional biological pathways
were upregulated (Supplemental Table 3.2). For example, both phagocytic and the NODlike receptor signaling pathways were upregulated post-treatment in individuals with
AEs, indicating that phagocytosis and downstream intracellular recognition of foreign
antigens are associated with AE development. Natural killer cell mediated cytotoxicity
and apoptosis are also both upregulated post-treatment in individuals with AEs. This
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broad immune activation suggests that there are many different activators of the host
response, and that no single antigen is responsible for AE development.
It is reasonable to suspect that Wolbachia is one of the main causes of AEs in W.
bancrofti-infected individuals, because we know that bacteria can induce strong proinflammatory host responses. However, compared to the vast body of literature
concerning bacterial molecules, virulence factors and toxins and the resulting proinflammatory host responses, very little is known about how filarial nematodes can
activate the immune system. This is turn might result in overestimation of Wolbachia
involvement in AE development. Previous studies have concluded that live filarial Mf
interact with dendritic cells and cause an upregulation of mRNA expression of proinflammatory molecules such as IL-8, RANTES, IL-1α, TNF-α, and IL-β (19). This
immune activation could be the results of secreted filarial proteins. It is also possible that
uncharacterized filarial components can signal through TLRs and contribute to the
development of AEs. For example, various protozoan ligands can signal through TLR2,
including GPI anchors from Trypanosoma cruzi (20), Leishmania major (21),
Plasmodium falciparum and Toxoplasma gondii (22), in addition to a T. cruzi-released
protein (23). Uncharacterized filarial proteins could be released by injured Mf and and/or
adult parasites after treatment and activate the host response. This hypothesis is presented
schematically in Figure 4.1B.
During infection the filarial parasites manipulate the host immune system and
induce a modified Th2 response in addition to a muted Th1 response, and this allows the
parasites to evade host defenses (24). Filarial parasites also down-modulate expression
and function of TLRs and MHC receptors (19, 25-27). These immunomodulatory effects
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are active parasite responses that require energy (e.g., to produce and secrete
immunomodulatory molecules). After treatment the parasites are injured or dead, and
vulnerable to attack from the host immune cells. These damaged parasites are no longer
able to manipulate the host immune response. IVM has even been shown to inhibit the
release of immunomodulatory molecules from the parasites (28). In onchocerciasis IVM
treatment resolves the parasite-induced immunosuppression and restores the immune
system (29, 30). Instead of the controlled release of specific immunomodulatory
molecules, a whole range of filarial antigens that are not normally accessible to the host
immune system are released into the circulation, and some of these could interact with
TLR receptors. Furthermore, a subset of the released foreign antigens could act as
substrates for C3b and activate the alternative complement pathway. This shift from a
chronic and controlled Th2 dominated response to an acute Th1 response may contribute
to development of AEs.

4.5

The pathogenesis of the Jarisch-Herxheimer reaction is similar to the pathogenesis
of post-treatment AEs in LF-infected individuals.
A phenomenon similar to the post-treatment AEs observed in LF-infected
individuals is common after treatment of more familiar infections. This phenomenon
where dead or dying microbes release foreign antigens after treatment that trigger proinflammatory responses and result in AEs is known as the Jarisch-Herxheimer reaction.
This reaction occurs after antibiotic treatment of spirochetal infections such as syphilis,
Lyme disease, leptospirosis, and relapsing fever. These infections are present world-wide,
and depending on the pathogen and the treatment course, a large percentage of
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individuals experience the Jarisch-Herxheimer reaction post-treatment (31). Unlike the
AEs experienced after LF-treatment, the Jarisch-Herxheimer reaction can be fatal with
the highest risk in pregnant women and in neonates (32-34). There are many similarities
between the AEs described in this thesis and the Jarisch-Herxheimer reaction. Nonendotoxin antigens are also hypothesized to cause the Jarisch-Herxheimer reaction, and in
Treponema pallidum a lipoprotein has been identified as the likely trigger for the reaction
(35). In Borrelia burgdorferi, the outer surface protein A lipoprotein stimulates cells by
activating TLR2-TLR6 and IL-1R signaling (36), and this is very similar to the
transcriptional signature of post-treatment AEs covered in chapter 3. Cytokine responses
during the Jarisch-Herxheimer reaction are also similar, with increases in TNF, IL-6, IL-8
and IL-10 (37, 38). Finally, it has also been suggested that the alternative complement
pathway is activated during the Jarisch-Herxheimer reaction (39). However, there are
also significant differences between the two post-treatment conditions. For example the
symptoms of the Jarisch-Herxheimer reaction occur much sooner after treatment; in
syphilis they start at four hours, peak at eight hours, and subside by 16 hours posttreatment (40), whereas in relapsing fever they starts at one-two hours, peak at four
hours, and subside by eight hours post-treatment (41). Contrary, the AEs observed after
LF-treatment peak at around 24-48 hours post-treatment (6-10). This is perhaps because
many of the drugs used to treat these spirochetal infections are bactericidal (42), and
could therefore be faster-acting than the LF drugs that interact with the host immune
system to exert their anti-filarial effects (28, 43-45). Furthermore, bacteria may
disintegrate much faster than nematode worms with their thick cuticle. The
transcriptomic response during the Jarisch-Herxheimer reaction has not been studied, so
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results from our filariasis study could provide a good starting point for studies of this
very similar phenomenon. It is also possible that lessons learned from the JarischHerxheimer field could be applied to LF-treatment. For example pre-treatment with antiTNF antibodies has been shown to significantly decrease the rates of adverse reactions
after treatment of relapsing fever (46, 47). However, using anti-TNF antibodies for
treatment or prevention of post-treatment AEs in LF-infected individuals as part of the
large MDA programs is not feasible, because the AEs are mostly mild to moderate and
anti-TNF treatments are very expensive (48).

4.6

Multiple antigens that contain the AD12 epitope circulate in the blood after
treatment.
In both the Papua New Guinea and Côte d'Ivoire cohorts we found that plasma
levels of circulating filarial antigen (CFA) increased 24-48 hours post-treatment in
individuals with AEs. Previous studies had described an increase in CFA levels 5-7 days
post-treatment (49, 50), but it was not known that CFA levels increase so soon after
treatment. This was also the first report of an association between post-treatment CFA
levels and the development of AEs. In the Côte d'Ivoire study we additionally discovered
that it was a whole range of different filarial proteins with the AD12 epitope that were
released post-treatment, and these lower weight AD12 antigens were not present pretreatment. This finding was surprising, because only the high molecular weight CFA had
previously been detected in the blood of W. bancrofti-infected individuals (51, 52).
Diagnostic tests for W. bancrofti that use the AD12 antibody against a carbohydrate
epitope on CFA are widely used (53). The current test used by the Global Program to
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Eliminate LF (GPELF) is the Alere Filariasis Test Strip (FTS) (54), but previously the
immunochromatographic card test (ICT) (52) was used to detect this antigen. The new
finding that multiple filarial antigens with the AD12 epitope are present in the blood posttreatment may help to explain the fact that some patients with heavy L. loa infections test
positive for filarial CFA (55). Individuals infected with L. loa sometimes have
exceptionally high parasite loads in their blood with Mf counts that can exceed 100,000
per mL (16). L. loa parasites cleared by the immune system may release crossreactive
antigens that do not normally circulate in the blood of infected individuals. The
carbohydrate epitope detected by the AD12 antibody is present on many nematode
proteins and not limited to W. bancrofti (56), so it would not be surprising if this epitope
were also present in antigens released when L. loa Mf die. Antigens immunoprecipated
with antibody AD12 (as described in section 3.5) from plasma of L. loa infected
individuals with false positive FST/ICT tests produce a similar pattern by Western blot to
antigens present in W. bancrofti post-treatment sera in Figure 3.5B (Dr. Philip Budge,
personal communication). This finding has a potential impact on GPELF, because neither
IVM nor DEC can be used safely in MDA campaigns in areas that are co-endemic for W.
bancrofti and L. loa because of the risk of serious AEs in people with heavy L. loa
infections (57, 58). Cross-reactivity of sera from people with L. loa infections in the
filarial CFA test limits the value of this important diagnostic test in such areas.
Fortunately, areas highly endemic for loiasis are restricted to a few countries in central
Africa (59).
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4.7

The search for a pre-treatment bio-marker associated with the development of posttreatment AEs.
One goal of this project was to delineate the pathogenesis of post-treatment AEs
by studying the host response during AEs. However, during the course of the project we
were interested to identify pre-treatment biomarkers or transcriptional profiles associated
with the development of post-treatment AEs. Eotaxin-1 was a promising candidate
identified in the Papua New Guinea pilot study, because baseline levels in individuals
who would go on to develop moderate AEs after treatment were significantly higher than
in individuals who had mild or no AEs (Figure 2.2). Unfortunately this result was not
confirmed in the larger sample cohort from Côte d'Ivoire. A possible explanation for this
disparity might be that the Papua New Guinea study participants had much higher
baseline Mf levels, and the moderate AEs in this group were more severe than the
moderate AEs in the Côte d'Ivoire study. All seven of the individuals in the moderate AE
group in the Papua New Guinea study had temperatures > 38°C after treatment, whereas
only three of nine individuals with moderate AEs in the Côte d'Ivoire study had
temperatures > 38°C. The maximum temperature recoded in the Côte d'Ivoire study was
38.5°C, whereas the maximum temperature recoded in the Papua New Guinea study was
39.7°C, and four of the seven Papua New Guinea individuals with moderate AEs had
temperatures > 39°C. However, the temperature data for the two studies are not fully
comparable, because axillary temperatures were recorded in the Côte d'Ivoire study, and
oral temperatures were recorded in the Papua New Guinea study. Thus, individuals in the
moderate AE group in the Côte d'Ivoire study were probably similar to the individuals in
the mild AE category in the Papua New Guinea study. Also, there was no significant
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difference in baseline eotaxin-1 levels between the mild AE and the no AE groups in the
Papua New Guinea study. Therefore, it is conceivable that eotaxin-1 might be a
biomarker for AEs, but only for more severe presentations with high fevers. The bottom
line here is that no cytokine was identified as a risk factor for developing AEs after
treatment in the Cote d’Ivoire study.
Based on results from the multiple logistic regression model, the best pretreatment predictor for AE development was baseline CFA level, and this variable was
better at predicting AEs than the baseline Mf counts. Multiple previous studies have
described the association between high baseline Mf loads and the development of AEs
(49, 60). CFA is already a widely used marker of W. bancrofti-infection, and it is
currently measured with the FTS diagnostic test. The FTS has many advantages over the
microscopy required to visualize and quantify Mf in the blood. Advantages include the
fact that day blood can be used for the FTS, whereas night blood has to be collected for
Mf testing. Mf microscopy also requires trained personnel, electricity, and good quality
equipment (61). The FTS is much easier and only takes 10-15 minutes to complete. The
intensity of the test line in the FTS (scored visually or by densitometry) is correlated with
filarial antigen levels as measured by ELISA (62). Thus FTS scores may be useful in the
field for identifying individuals with increased risk of AEs after LF-treatment who might
benefit from post-treatment paracetamol or ibuprofen.
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4.8

Is there a pre-treatment transcriptional signature that is associated with the
development of AEs after treatment of lymphatic filariasis?
This study was not specifically designed to identify a pre-treatment transcriptional
signature that could predict AEs. We were not able to identify a single gene that was
significantly predictive for development of post-treatment AEs. That would require many
more samples than we had in this study.

To get around this we used Gene Set

Enrichment Analysis (GSEA) as described in section 3.5. With this method we were able
to identify biological pathways that were overrepresented in the two pre-treatment AE
groups. As discussed in chapter 3, pre-treatment samples from individuals who did not
develop AEs were enriched for various B-cell pathways, and this finding was in
agreement with the CIBERSORT data, that showed that memory B-cells were
significantly higher pre-treatment in individuals who did not develop AEs. Additionally,
these data were also consistent with the GeneQuery results that identified multiple B-cell
signatures to be similar to the gene expression profile pre-treatment in people who did not
develop AEs after treatment. This finding was surprising, and it is difficult to explain.
Perhaps individuals with immune systems primed for humoral responses are protected
from AEs. Another explanation could be that individuals with stronger humoral immune
responses are better at clearing Mf, and as a result of lower Mf levels pre-treatment
therefore experience fewer AEs after treatment. However, the RNA-seq data was
obtained from nine matched-control subjects that did not significantly differ in baseline
Mf levels between individuals that developed AEs and individuals that did not develop
AEs. It is also difficult to understand how this information could be used by GPELF. It
would be interesting to test whether AE rates following treatment of LF are decreased in
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persons who have recently received vaccines that induce vigorous antibody responses to
microbial antigens. It would be difficult to do this in practice, because vaccine programs
usually target children and AEs following MDA for LF are more common in adults.
There was no clear pattern in the pathways overrepresented in pre-treatment
samples from individuals who developed post-treatment AEs. However, two pathways
identified by GSEA were associated with the cytochrome P450 pathway. Cytochrome
P450 enzymes metabolize endogenous and exogenous chemicals including many drugs
(63). This finding was surprising, because the two microfilaricidal drugs IVM and DEC
do not have active metabolites that need cytochrome P450 to be activated. IVM is
actually metabolized into inactive metabolites by cytochrome P450 (64), whereas DEC is
metabolized independently of cytochrome P450 (65). ALB, on the other hand, is a
prodrug, and it is metabolized by cytochrome P450 into its active metabolite albendazole
sulfoxide (66). Albendazole sulfoxide is then further metabolized into the inactive
albendazole sulfone by cytochrome P450 (66). However, both albendazole and
albendazole sulfoxide have very limited short term effects on Mf or adult filarial
parasites, and AE rates after ALB treatment in LF-infected individuals are very low (67).
Consequently, increased pre-treatment levels of cytochrome P450 might result in faster
breakdown of the AE-causing mircrofilaricidal drug, IVM. This might be expected to
decrease drug levels, anti-filarial activity, and the rate and severity of AEs. Thus the
observed GSEA results are unexpected and for now, unexplained. Additional studies will
have to be conducted to verify whether there is any link between cytochrome P450 and
post-treatment AEs in LF-infected individuals.
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4.9

Future directions.
A possible future study would be to investigate AE-associated genes and
cytokines in in vivo or in vitro models. Peripheral blood mononuclear cells (PBMCs)
from LF-infected individuals could be stimulated with different filarial-worm
components or whole filarial extract, and responses could be assessed by qRT-PCR and
cytokine ELISAs. The main problem with this approach would be to obtain the PMBCs
from LF-infected individuals, because it is very difficult to isolate and preserve PBMCs
in endemic countries due to the lack of laboratory facilities in the remote areas where
parasite densities and the risk of AEs are the highest. Another possible approach would
be to develop an animal model for treatment-induced AEs in LF. The most appropriate
model would be the L. sigmondontis mouse model (68, 69). An advantage of this model
is that the mouse is a permissive host that develops an adaptive immune response to the
parasite (70). Tools are readily available for measuring gene expression and cytokine
levels in mice, and studies with various knock-out mice, such as TLR knock-outs, could
be very informative. A disadvantage of this model is that the mice naturally clear the
infection after 3-4 months (71). Also maintenance of the life cycle in the laboratory is
challenging, because it requires both cotton rats (difficult to use in the USA) and mites
(72). Another suitable model would be the B. malayi-gerbil model of infection (73). An
advantage of this model is that B. malayi is one of the three filarial parasites that cause
LF in humans, and it is very similar to the other two species (74). Additionally, the gerbil
is also a permissive host for the Wolbachia-free filarial parasite A. viteae (75). By
comparing post-treatment AE presentations in these two gerbil models, one could identify
the contribution of Wolbachia to the development of AEs. The gerbil model is easier to
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maintain in the laboratory than the L. sigmodontis mouse model, because B. malayi and
A. viteae-infected gerbils can be purchased (76), and the whole lifecycle does not have to
be maintained. A disadvantage of the gerbil model is the tools for genetic studies are
limited compared to those for mice, and there are no knockouts available. Neither of
these models has been used to study AEs after anti-filarial treatment, although it is known
that infected gerbils experience AEs after DEC treatment (77).
This study represents the first RNA-seq analysis of LF-infected individuals, and
we were therefore not able to answer all the important questions and complete all the
relevant comparisons in this one study. An important comparison that needs to be
completed is to compare gene expression profiles of LF-infected and uninfected
individuals. This has previously been done with microarrays (78), as mentioned in the
introduction. If we added uninfected individuals who were treated with ALB/IVM or
IDA as a control group, this could help us to weed out genes that change expression
following treatment in uninfected people. Samples for this type of study are already
available, because pre- and post-treatment buffy coat samples were collected during the
Côte d'Ivoire pharmacokinetic trial (Clinicaltrials.gov NCT # 02845713) (17) where W.
bancrofti-infected and uninfected individuals were treated with IDA. It would also be
interesting to look at gene expression and infection status (both antigen and Mf) from the
individuals in our study at one and/or two years post-treatment. This would enable us to
identify changes in gene expression that occur following successful treatment. One
challenge with this idea is that most people treated with one or two doses of IDA or
ALB/IVM do not completely clear the infection as they remain antigen positive even if
they are Mf negative. Another interesting analysis would be do look at the gene
150

expression profiles at 24 hours post-treatment to identify any difference in host responses
between the individuals that successfully cleared their Mf at one or two years posttreatment, and the individuals that had suboptimal treatment responses.
The methodology used for this project could be adapted to other neglected
tropical diseases, including the two filarial parasites that cause the most severe posttreatment AEs: O. volvulus and L. loa (57, 58, 79). L. loa does not contain Wolbachia, so
it would be very interesting to see if host responses during AEs in L. loa-infected
individuals differ from those that occur in W. bancrofti-infected individuals. Serious AEs
in L. loa-infected individuals often occur in the central nervous system, and such AEs are
not seen after treatment W. bancrofti. However, is not clear whether peripheral blood
leukocytes would be informative for studies of CNS AEs following treatment of loiasis.
The main AEs in O. volvulus-infected individuals are skin-related as the adult parasites
live in the subcutaneous tissue and the Mf live in the upper dermis (16). For
onchocerciasis it might therefore be interesting to collect skin snips of healthy tissue and
from tissue affected by AEs. These samples could be from the same individual, and that
could eliminate inter-individual differences and resulting noise in the RNA-seq data.

4.10

Conclusions.
Overall the rate of AEs in LF MDA programs might seem low, because AEs
mainly occur in infected individuals. Additionally, one might argue that most AEs that do
occur are mild and that they should not be of great concern for researchers or health
officials. However, an astounding 6 billion LF MDA treatments have been delivered to
hundreds of millions of individuals across the globe, and even mild or moderate AEs can
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have a huge impact on the success of LF elimination programs based on MDA. This
dissertation research has described changes in host gene expression and cytokine profiles
associated with post-treatment AEs in LF-infected individuals, and the work has
identified pathways that could be targeted to decrease or eliminate AEs, such as TLR2,
NF-κB, TNF and the STAT transcription factors. TLR2, NF-κB, and STAT have all been
identified as possible cancer drug targets (80-82), and anti-TNF antibodies are widely
used to treat autoimmune disorders, so maybe developments in these other fields will
benefit LF patients in the future. Widespread use of expensive molecularly targeted
therapy is obviously not well suited for the huge global LF program, but such treatments
might be used in the small number of persons who experience serious AEs. Our results
are consistent with the hypothesis that Wolbachia lipoprotein activates TLR2-TLR6
resulting in AEs, but additional uncharacterized filarial antigens are probably also
involved (Figure 4.1). Finally, based on the knowledge learned from this dissertation we
will now be able reassure endemic populations and communicate to them that the AEs
experienced after LF treatment are evidence that the medications that they have taken are
working and killing harmful parasites in their bodies.
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Figure 4.1: Proposed signaling pathway of Wolbachia and filarial antigens.
[A] An updated overview of the proposed mechanisms by which Wolbachia contributes to the
pathogenesis of adverse events after LF treatment. [B] An overview of the proposed mechanisms
by which uncharacterized filarial antigens contribute to the pathogenesis of adverse events after
LF treatment.
Figure is adapted from Taylor MJ, Cross HF, Ford L, Makunde WH, Prasad GB, and Bilo K.
Wolbachia bacteria in filarial immunity and disease. Parasite Immunol. 2001;23(7):401-9.
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